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CHAPTER I 
 
INTRODUCTION 
 
 Biomechanics play a vital role in vascular biology, affecting the cells of 
arteries and veins under both physiological and pathological conditions.  While 
many studies have shown that the development of atherosclerosis is particularly 
associated with biomechanical stress, the effect of stress on the cells in an 
established atherosclerotic plaque is less well studied.  This document aims to 
define the role of biomechanics in the vasculature, particularly in vascular smooth 
muscle cells (VSMCs) of large arteries, in normal and atherosclerotic conditions.  
This will include a discussion of mechanosensing, mechanotransduction, and the 
physical adaptations by cells to biomechanical stress.  Finally, SPRR3, a 
mechanically sensitive protein which is localized to atheromas, will be used as an 
example of VSMC adaptation to stress. 
 
Normal vessel biomechanics 
 There are two primary stresses experienced by normal large arteries: 
shear stress and cyclic strain.1  By contrast, veins experience only very low levels 
of either stress.2  Shear stress is the frictional force experienced by the 
endothelium as blood flows through the lumen.  Shear can be laminar, as it is in 
areas of uninterrupted flow, or turbulent, which occurs at curves or branch points.  
While endothelial cells (ECs) are the primary sensors of shear stress, some 
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stress may be relayed to the VSMCs by transmural transmission through the 
extracellular matrix (ECM).3  Cyclic strain is the tangential force on the arterial 
wall during systole.  Unlike shear stress, cyclic strain primarily affects both ECs 
and VSMCs, and to a lesser degree, adventitial fibroblasts.2  The effects of cyclic 
strain on VSMCs has been the subject of much study in the recent decades, and 
many methods have been developed for exposing cells and tissues to cyclic 
strain both in vitro and in vivo (an in depth discussion of the topic can be found in 
a review by Brown).4  While cyclic strain is a major determinant of normal VSMC 
physiology, for example, by regulating proliferation and apoptosis, it also plays a 
pivotal role in various pathologies.  These include hypertension, vein-graft intimal 
hyperplasia and failure, restenosis, and atherosclerosis.5 
 
Plaque biomechanics 
 Atherosclerosis is a disease of large arteries characterized by the 
accumulation of lipid, ECM, and cells within the arterial intima.6  As the 
underlying cause of most myocardial infarctions and strokes, atherosclerosis is 
ultimately responsible for up to 50% of all deaths in the United States, resulting in 
over $400 billion dollars in health care fees in the U.S. annually.5, 6  In light of this 
toll on society, it is of great importance to understand atherosclerosis in order to 
improve detection and treatment of the disease.  Much of the existing research in 
the field has focused on the role of lipids and inflammation in atherosclerosis.  
However, this manuscript will address the role of biomechanics in atherosclerotic 
disease development and progression.   
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 Atherosclerosis occurs in large and medium-sized arteries and develops 
over time, starting with fatty streaks, progressing to intermediate lesions, and at 
the worst stage of the disease, advanced and complicated lesions (Figure 1-1).7-9  
Brief descriptions of each of these lesion types in human vasculature, as laid out 
by the American Heart Association Committee on Vascular Lesions of the 
Council on Arteriosclerosis, are as follows.  Normal arterial intima consists of that 
part of the arterial wall from the endothelium down to the luminal edge of the 
media, as demarked by the internal elastic lamina.  Thus, the intima comprises 
the endothelium, ECM (primarily collagens and elastin), and occasional VSMCs.  
Thick regions of the intima can be found throughout arteries (either focal or 
diffuse), and denote adaptive responses to physiological changes in 
hemodynamics.7  The earliest pathological lesions are fatty streaks, or lipid 
deposits within macrophage foam cells in the intima.  These may be so small as 
to be only microscopically detectable, whereas later lesions are generally visible 
to the naked eye upon autopsy.8  As the lesion progresses to a true atheroma 
and foam cells continue to accumulate, VSMCs migrate into and proliferate within 
the intima, thereby increasing plaque size, secreting collagen to generate a 
fibrous cap over the plaque.  Moreover, VSMCs and foam cells secrete matrix 
metalloproteinases (MMPs) which break down and remodel ECM molecules such 
as collagen and elastin.9  An advanced atheroma contains all these components 
and usually a necrotic core, calcifications, and in the most advanced state, 
fissures and hemorrhages (Figure 1-1c).10  VSMCs in this context undergo a 
number of processes which are pivotal in the process of atherosclerotic 
  3
  
Figure 1-1 
 
Figure 1-1 
Atherosclerotic progression is a complex process involving many cell 
types and ECM.  The earliest events in atheroma formation are endothelial 
dysfunction and lipid accumulation in the arterial intima leading to macrophage 
infiltration and foam cell formation (a).  As VSMC migrate and proliferate within 
the intima, an early lesion forms (b).  If the plaque is relatively VSMC-poor (due 
to apoptosis), especially with a lipid-rich necrotic core and thin fibrous cap, the 
plaque is vulnerable to fissure and rupture (c).  However, if VSMCs are abundant 
within the lesion and actively secrete ECM to generate a thick fibrous cap, then 
the plaque will remain relatively stable and is unlikely to cause a clinically-
recognizable event (d). 
4
Table 2-1:   Primers used for qRT-PCR 
 
  Tm
Product 
Size Primer Sequence 
18S Forward 5'-CGCCGCTAGAGGTGAAATTCT-3' 
       Reverse 
60o C 100 bp 
5'-CGAACCTCCGACTTTCGTTCT-3' 
    
MMP-2 Forward 5'-ATCGCTCAGATCCGTGGTG-3' 
       Reverse 
54o C 51 bp 
5'-CCAAATGAACCGGTCCTTGA-3' 
    
Elastin Forward 5'-TTCCCCGCAGTTACCTTTCC-3' 
       Reverse 
54o C 144 bp 
5'-AACCACCGCACCTGCAGA-3' 
    
Sciellin Forward 5'-CCTGAAAACACCTGACACCA-3' 
       Reverse 
52o C 145 bp 
5'-TCCTGGCATTCACTTTAGCA-3' 
    
Periplakin Forward  5'-ACTGGAGTGACCGCAACCTC-3' 
       Reverse 
58o C 127 bp 
5'-TGAAATTCTCATACTGGCGCC-3' 
    
SPRR3 Forward 5'-ATGTCCTTCAACGGTCACTCC-3' 
       Reverse 
52o C 96 bp 
5'-CTCTTCGGTTGGTGGTCTAC-3' 
    
Plakoglobin Forward 5'-CAACCAGGAGAGCAAGCTGAT-3' 
       Reverse 
60o C 70 bp 
5'-GTTACGCATGATCTGCACGAG-3' 
    
Galectin 7 Forward 5'-CACGGTGCTGAGAATTCGC-3' 
       Reverse 
60o C 52 bp 
5'-ATGGAACCTGCTGGCATTG-3' 
    
Envoplakin Forward 5'-CTTCCTGAACCTGTGTATCTGCC-3' 
       Reverse 
60o C 65 bp 
5'-GGAACCGGCGGTAGTCCT-3' 
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development.  These include VSMC migration, proliferation, and switching from a 
contractile to a synthetic state.11  All of these changes in vessel wall content 
result in an atheroma-specific microenvironment which is significantly different 
than the adjacent vasculature.   
 
VSMCs in atherosclerosis 
VSMCs accumulation is a hallmark of moderate to advanced 
atherosclerotic plaques.  Within the plaque, VSMCs act in diverse manners, 
primarily by modulating proliferation, inflammation, ECM modulation, and 
contraction (Figure 1-2).12  VSMC proliferation and hypertrophy within the plaque 
is largely mediated by platelet-derived growth factor (PDGF) and transforming 
growth factor beta (TGFβ) which are both sensed and synthesized by the 
VSMCs.4, 13  Early in plaque development, VSMCs secrete inflammatory 
mediators, such as monocyte chemoattractant protein 1 (MCP-1), interleukins, 
and tumor necrosis factor-α.  These, along with surface expression of adhesion 
molecules such as intercellular adhesion molecule-1 and vascular cell adhesion 
molecule-1, promote macrophage infiltration and accumulation.12  It has been 
shown that VSMCs within an atherosclerotic plaque undergo phenotypic 
switching, moving from a more contractile to synthetic state.13  As such, VSMCs 
along with other local cells, such as macrophage foam cells, modify the local 
atherosclerotic milieu by synthesizing ECM molecules, primarily collagens I and 
III as well as MMPs which degrade and remodel the ECM.14  This remodeling is 
critical in determining the stability of the plaque; increased MMP activity is 
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Figure 1-2 
 
Figure 1-2 
The VSMC plays a central role in atherosclerotic progression. 
VSMCs in atheromas function in four capacities.  Contraction occurs in response 
to vasoactive substances such as angiotensin II and endothelin.  VSMCs 
proliferate and hypertrophy by stimulation with PDGF and TGFβ.  They also 
interact with the extracellular space by making and remodeling ECM and by 
binding it through integrins αvβ3 and α1β1.  Finally, there is a significant release 
of inflammatory molecules into the local milieu. 
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thought to undermine plaque stability, thereby increasing the risk of rupture.15, 16  
Although they are in a primarily synthetic state, VSMCs within atheromas are still 
capable of responding to contractile stimuli, such as endothelin-1 and 
angiotensin II, which are present in the atherosclerotic plaque.17-19  Thus, the 
VSMC is a key player in atherosclerosis development and progression.  Gaining 
further insight into these cells, particularly as they respond to a lesser-studied 
stimulant, biomechanical stress, will aid in the study and treatment of 
atherosclerosis. 
 
Altered stress/strain at branch points 
 It has long been known that biomechanical forces promote 
atherosclerosis, specifically at curves, branch points, and bifurcations.20  Thus, 
atheromas most often arise in the branching coronary and carotid arteries, in the 
abdominal aorta at the branches for the abdominal arteries, and around the iliac 
bifurcation.21  The effect of shear stress on ECs has long been related to the 
development of atherosclerosis.  At regions where the blood flow is significantly 
disrupted and low, turbulent shear stress alters cellular behavior, leading to 
endothelial dysfunction.  Aspects of this state include a generalized inflammatory 
state of ECs, which gives rise to generation of reactive oxygen species, altered 
surface markers, and increased lipid clearance into the intima.22  Furthermore, 
though it is less-well understood, the cyclic strain at these points is also 
significantly affected, with the direction and magnitude of stretch being different 
from areas of the arteries which are not atheroma-prone.  Hence, these altered 
  8
biomechanics that impact plaque initiation also impact VSMCs within an 
established plaque.11 
 
Effect on VSMCs  
 The effect of shear stress on VSMCs has been investigated, though not to 
the same extent as on ECs.  In addition to experiencing “by stander” shear stress 
via transmural transmission, certain surgical procedures denude the 
endothelium, directly exposing VSMCs to shear stress.1, 22, 23  Studies on the 
effect of shear stress in VSMCs have considered the mechanotransduction of 
shear and resulting physical changes in the cells.  For example, twenty-four 
hours of in vitro shear stress suppresses VSMC proliferation.  The same report 
demonstrated a 2- and 5-fold upregulation of TGFβ and tissue-type plasminogen 
activator, respectively.23  Further studies suggest the decreased proliferation may 
be due to the suppression of PDGF receptor expression and Src phosphorylation 
by non-uniform shear stress.24  However, in another non-laminar shear stress 
model in which stress exposure was prolonged (10 days), VSMCs demonstrated 
75% increased proliferation in an Erk1/2-dependent manner.26 
 
Altered biomechanics within the plaque 
An established atherosclerotic plaque itself is subject to alterations in 
biomechanical stress and experiences distinct stresses compared to those felt by 
healthy vessels.  Recent studies have shown that biomechanical stress caused 
by altered flow not only leads to atherosclerosis, but atherosclerosis itself alters 
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local biomechanics (Figure 1-3).27-29  Recently, sensitive technological 
innovations have become available, such as intravascular ultrasound, which 
revealed that even early atherosclerotic lesions significantly affect vessel 
compliance.27, 30  On the cellular level, there are many factors in the development 
of atherosclerosis which can affect vessel stiffness.  For example, as the disease 
progresses VSMCs proliferate and hypertrophy and inflammatory infiltrates 
(macrophages and lymphocytes) further alter local cellular density.  ECM 
synthesis and remodeling by macrophages and VSMCs further promotes local 
stiffening.  Excess free cholesterol in the plaque can be taken up into the plasma 
membranes of the resident cells, promoting rigidity of the individual cells.21, 22  As 
the plaque progresses, the interior can necrose and calcify, further altering 
vessel compliance.5, 12  These changes in vessel compliance necessarily have an 
effect on the cells resident in the vessel, such as VSMCs.  However, little is 
understood about the resulting molecular changes of VSMCs as they adapt to 
plaque biomechanics and their impact on plaque stability. 
 
Fibrous cap 
 
One of the vessel-stiffening events evident in mature plaques is the 
generation of a fibrous cap which plays an important role in plaque stability.  The 
fibrous cap is a structure made up of VSMCs and collagen, which separates the 
lumen from the atheroma and stabilizes the plaque against rupture.23, 24  A stable 
plaque is defined by a thick fibrous cap, extensive VSMC content, few 
macrophages, and a minimal necrotic core.  On the other hand, an unstable, 
rupture-prone, or “vulnerable” plaque is defined by a thin fibrous cap, profound 
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Figure 1-3 
 
 
Figure 1-3 
Interplay between biomechanics and atherosclerosis.  Altered shear stress at 
branch point and curves is a well-known initiating step in atherosclerosis.  The 
atherosclerotic plaque, in turn, promotes increased arterial compliance and 
distendability as lipid, cells, and ECM accumulate in the vessel wall.  As the 
vessel wall stiffens, it alters blood flow and changes the local hemodynamics.  
Altered stress then further promotes atherosclerosis through mechanosensing 
resulting in changes in gene expression, thereby promoting increased plaque 
development. 
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macrophage infiltration, low VSMC content, and a large lipid- and calcium-filled 
necrotic core.25  In the absence of a thick, stiff, protective top layer, the unstable 
plaque is prone to fracturing under the continuous shear and cyclic stresses.29, 34   
Thus, biomechanical alterations in the vasculature, particularly in and around 
atherosclerotic plaques, are of significant biological and clinical interest.  Of 
particular interest is how VSMCs, particularly those within the atherosclerotic 
microenvironment, sense and adapt to mechanical stress by altering gene 
regulation and cellular behavior.  Therefore, the remainder of this document will 
focus on the mechanisms by which VSMCs sense stress and respond to it.   
 
 Mechanosensors—Integrins  
Many proteins have been implicated in mechanosensing by VSMCs, 
including membrane oxidase NADH/NADPH, stretch-activated ion channels, G-
protein coupled receptors, integrins, and others.36-39  In the context of the 
atherosclerotic plaque, VSMCs are surrounded by ECM, primarily type I collagen, 
and to a lesser extent elastin, vitronectin, and fibronectin.7  Cells relate to and 
sense this environment through integrin-ECM interactions, thus making this 
interface an important focus of study.5  The integrins are a large family of 
heterodimeric cell adhesion receptors which primarily bind extracellular matrix.  
There are 18 α and 8 β subunits which heterodimerize into 24 unique integrins.26  
The majority of the work with mechanotransduction in VSMCs has implicated β1, 
β3, and various corresponding α subunits as sensors for mechanical stress that 
transduce signals through numerous pathways.41-45  Integrins are ideal cellular 
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sensors of biomechanical stress, as they link the ECM to the cell cytoskeleton 
through transmembrane domains and can thereby transmit signals intracellularly.  
When they are not bound to ECM, integrins reside in an inert, or resting, state in 
which the ECM-binding sites are hidden.  However, when triggered by various 
signals, both subunits undergo a conformational change to expose the binding 
sites and can thus bind to the ECM.27  Classical integrin signaling begins by 
binding of a single heterodimer to its ligand which triggers clustering of other 
integrin heterodimers and their binding to the same ligand.28  This leads to 
recruitment of various signaling and structural proteins to the intracellular end of 
the integrins, forming focal adhesions.29  From focal adhesions, signals are 
transmitted within the cell, regulating various processes including gene 
regulation, cytoskeletal arrangement, and proliferation.30  Integrin activation can 
occur not simply through the binding to specific ECM molecules, but also by 
sensing tension in the ECM.31  Furthermore, integrins, ECM components, the 
cytoskeleton, and the nucleus are all connected such that a mechanical stress at 
any of these sites can be transmitted to the others.51  The integrins of particular 
interest with respect to mechanosensing within atheromas, are α1β1, α7β1, and 
α8β1, though many others have been implicated in VSMC biology.32  Thus, 
extracellular stress and tension can be transmitted through the ECM via integrins 
to promote intracellular signaling events and alter gene regulation, as well as 
transferring the forces to the cytoskeleton.   
 The interaction between ECM and integrins can be modulated by cyclic 
strain which alters ECM production and remodeling.  For example, human 
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VSMCs under prolonged cyclic strain (24-96h) were shown to upregulate 
collagen and fibronectin.  This was further shown to be the result of synthesis 
and release of TGFβ by the cells in response to stretch; incubation with TGFβ-
blocking antibodies was sufficient to abrogate collagen synthesis in response to 
stretch.33  In another report, type I collagen and fibronectin synthesis was 
upregulated in VSMCs following 12-48h cyclic strain, with a maximal expression 
at 12h.  Fibronectin regulation was shown to be dependent on signaling through 
the angiotensin type II receptor.55  Furthermore, cells exposed to 24h cyclic strain 
upregulated expression of type I collagen through Akt activation.34  Static stretch 
of VSMCs has been shown to significantly regulate elastin transcription as well.35  
Matrix remodeling genes are also affected by stretch.  Asanuma et al, showed 
that human VSMCs exposed to up to 72h static or cyclic strain modulate MMP-2 
and -9 synthesis and secretion.36  In these cases, the expression of ECM and 
matrix-regulating proteins is important for vessel remodeling and adaptation to 
biomechanical stress.   
Integrin activation can occur not only by binding their substrate, but also 
by mechanical activation via substrate tension.40, 58  For example, it was shown 
that distinct signaling occurred downstream of the β1 integrin when activated by 
binding to an RGD peptide substrate versus activation from mechanically pulling 
on it through the same substrate-receptor interaction37.  Specifically, cAMP levels 
increased, by applying stress through the integrin.37  In another report, anti-
integrin antibody-coated magnetic beads were allowed to adhere to cells, thereby 
binding to and clustering integrins.  While this binding did produce an increase in 
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total cellular protein phosphorylation compared to untreated cells, when a 
magnetic field was used to apply stress through the integrins, an increase in total 
protein phosphorylation was observed.38  Furthermore, a similar study 
demonstrated that using optical tweezers to apply stress through integrins 
generated cytoskeletal stiffening around the focal adhesion.39  These studies 
serve to distinguish the distinct responses of integrins to chemical and 
mechanical input.  
 There are many known pathways by which integrins transduce 
biomechanical stress into a chemical signal within the cell.  Plating cells on 
different substrates has differing effects, depending on which integrin 
heterodimers are affected.  It has been speculated, though not conclusively 
shown, that the α subunit is the actual mechanosensor, which then prompts the β 
subunit to undergo activation through an intracellular signal.40  Reusch, et al, has 
shown that VSMCs differentially activated Erk1/2 and JNK when exposed to 
cyclic strain on either laminin or pronectin (an RGD-containing peptide) matrices, 
each of which engage different integrins.41  Integrin αvβ3 has been shown to be 
required for the mechanosensitive activation of PI3K/Akt in rat VSMCs exposed 
to cyclic strain for 15min.63  VSMCs that were stressed by direct application of 
force to various integrins through coated magnetic beads showed activation of 
Erk1/2 specifically through β3, but not α2 or β1 integrin subunits.45  However, 
another study showed the opposite; applying direct biomechanical stress through 
either integrins β1 or α2 produced a global increase in tyrosine phosphorylation, 
specifically an increase in Erk1/2 phosphorylation.38  The discrepancy between 
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these studies may be due to different methodology for applying stress.  A similar 
study demonstrated an increase in cAMP levels, as well as phosphorylation of 
CREB and nuclear PKA-c, following mechanical stress application to the RGD-
binding integrins.37  Thus, a variety of downstream signaling events have been 
linked to mechanical stress on integrins.  The pathway of action varies by 
integrin/ligand interactions, duration of stress, and mechanism of strain, 
nevertheless, it is clear that integrins play a significant role as mechanosensors.  
Notably, while integrins have been the most studied of the ECM-receptors, they 
are not the only ones which serve as mechanotransducers.  The elastin-laminin 
receptor was demonstrated to transduce mechanical stimuli into cultured 
VSMCs.64, 65   
 
Physical Changes Resulting from Biomechanical Stress 
 As an atherosclerotic plaque develops and forms as a result of previously 
described changes (ECM expression and remodeling, cellular infiltration and 
accumulation, etc), the region in and around the atheroma becomes increasingly 
different from the surrounding vasculature.  These changes affect vessel 
compliance and result in a unique environment in which cells within the plaque 
experience stress differently than the neighboring tissue.42  This distinctive milieu 
produces a distinct set of responses in VSMCs, including altered cytoskeletal 
arrangement, changes in VSMC proliferation, apoptosis, and phenotype, but 
most of these changes are determined by altered gene expression.  VSMCs 
modulate an array of genes in atherosclerosis, but only in the presence of the 
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unique plaque microenvironment.  For example, our lab and others have 
demonstrated expression of the integrin subunit α1 on VSMCs to be largely 
restricted to atheromas, though expression is rarely observed in VSMCs of 
normal vasculature.43, 44  This is the result of the influence of the atheroma 
microenvironment, which is rich in various cytokines such as TGFβ, PDGF, and 
MCP-1 that modulate VSMC gene expression and behavior.45, 46  Moreover, in 
the presence of this microenvironment, biomechanical stress will differentially 
affect the VSMCs; for example, as the α1β1 integrin is present only within the 
atheroma, only there will it transduce cyclic strain down a specific pathway to 
regulate specific genes.43  Thus, the response of VSMCs to biomechanical stress 
is ideally studied within the context of a specific setting such as the 
atherosclerotic microenvironment, and should be considered as a caveat when 
applying in vitro studies of biomechanics and VSMCs to the molecular 
understanding of atherosclerosis.   
 
Gene Transcription 
The primary manner in which physical changes arise following biomechanical 
stress is through modulation of gene transcription.  For example, many groups 
have shown that cyclic strain activates α-actinin expression, thereby promoting 
VSMC differentiation.73, 74  Other studies have demonstrated upregulation of a 
variety of genes in response to cyclic strain.  For instance, studies have shown 
that chronic stretch increases ECM production, as well as integrin expression on 
VSMCs.43, 44, 53    VSMCs exposed to cyclic strain for 24h have been shown to 
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upregulate transcripts of MCP-1.  This effect is partially blocked by inhibition of 
PKC and tyrosine phosphorylation.47  Human aortic VSMCs exposed to 20% 
cyclic strain demonstrated a 2-fold increase in protease-activated receptor-1 
(PAR-1) in an NADPH oxidase-dependent manner, and was synergized in the 
presence of fibroblast growth factor.  Paradoxically, shear stress downregulated 
the expression of PAR-1.48  Exposure to 10% cyclic strain for 4h produced a 3.3-
fold increase in expression of VEGF from VSMCs.49  Another group has shown 
that expression and shedding of syndecan-1, -2, and -4, cell surface heparin 
sulfate proteoglycans which act as cell-surface receptors were increased with 
cyclic, but not static strain, in human aortic VSMCs.78, 79  Furthermore, the 
proliferation-suppressing protein iex-1 is induced is in VSMCs exposed to 24h 
cyclic strain, downstream of NF-κB activation by mechanical strain.80  Using 
magnetic twisting cytometry, D’Addario, et al. showed a force-dependent 
regulation of Filamin A through the β1 integrin.50  These and other changes in 
gene expression have a variety of effects on VSMCs, including changes in the 
cytoskeleton, apoptosis, proliferation, and phenotypic state.  Cyclic strain also 
affects gene expression in the atheroma in cells other than VSMCs.  Low-levels 
of cyclic strain (0%-3%) on cultured monocyte/macrophages induced expression 
of class A scavenger receptor by up to 3.5-fold.  This was consistent with the 
finding that many macrophages in atherosclerotic lesions of ApoE-deficient mice 
express the class A scavenger receptor, and this effect is augmented by inducing 
hypertension, and thus increasing physiological cyclic strain.51  This further 
demonstrates the importance replicating the atheromatous milieu in vitro to 
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recapitulate physiology; not only do VSMCs respond to the stress, but other cells, 
particularly macrophages which would not otherwise be exposed to cyclic strain, 
are also affected by events specific to the atheroma. 
 
Cytoskeleton   
In the artery wall, ECs align along the direction of blood flow.  However, 
VSMCs are arranged in a helix around the artery and are orientated 50°-70° 
relative to the axis of cyclic strain.  A well-documented in vitro response of 
VSMCs to cyclic strain is the remodeling of the cytoskeleton such that the cells 
orient themselves perpendicular to the direction of stretch.66, 67  This is believed 
to be due to rearrangement of the cytoskeleton, particularly actin stress fibers.52  
There are many possible molecular mediators of this effect.  Standely, et al., 
showed a mechanism of alignment which was partly dependent on nitric oxide 
(NO).  NO synthase (NOS) inhibition in VSMCs exposed to 48h cyclic strain 
blocked cellular alignment perpendicular to the direction of stretch.  Interestingly, 
neither supplementing NOS activity nor NO presence had any affect on VSMC 
alignment, suggesting that the mechanism may diverge from the more commonly 
recognized pathways of NOS action.69  This is supported by another report in 
which VSMC alignment was shown to be dependent on reactive oxygen species 
and p38 MAPK, but not on PI3K, JNK, Erk1/2, or ion channels.53  
 Cytoskeletal proteins themselves can respond to cyclic strain.  Rat aortic 
VSMCs exposed to acute 15% cyclic strain demonstrate translocation of zyxin 
from focal adhesions to the nucleus, where it affected expression of 
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mechanosensitive genes.  However, this was a transient effect; following long-
term strain (6h), the majority of zyxin returned to the cytoplasm.71  While not a 
cytoskeletal element, the transcription factor Egr-1 relocated within the cell in 
response to stress.  Egr-1 was not only increased in neonatal rat VSMCs 
exposed to cyclic strain, but was also shown to translocate to the nucleus in 
response to the strain.72   
 
Apoptosis 
 VSMC apoptosis has various effects on the atherosclerotic plaque, and 
can modulate plaque stability, calcification, and inflammation.15  Generally, cyclic 
strain increases VSMC apoptosis.  Many groups have studied the mechanisms 
by which this occurs, with the goal of eventually reversing the effect.  For 
example, the laboratory of Qingbo Xu has performed many studies on the 
signaling resulting from cyclic strain on VSMCs, particularly as it results in VSMC 
apoptosis.  They have shown that when exposed to cyclic strain venous VSMCs 
undergo apoptosis through the β1 integrin in a p53- and p38-dependent 
manner.2,44, 82  Another group has shown that 10% stretch in VSMCs plated on 
type I collagen induced cell cycle arrest compared to static controls, through p21 
activation, along with a decrease in Rb phosphorylation.54  Additionally, 25%, but 
not 7% cyclic stretch of porcine VSMCs induced a three-fold increase in 
apoptosis through JNK and p38 compared to static controls.  This was possibly 
due to activation of the TNFα receptor 1.85  The phenotype of VSMCs can also 
affect their apoptotic response to cyclic strain.  Relative to VSMCs in a 
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proliferative, de-differentiated state, quiescent, differentiated cells exposed to 
10% cyclic strain underwent up to 25% more apoptosis.55  Finally, another group 
has shown that calpain expression partially attenuates strain-induced apoptosis, 
such that in the absence of calpain or with a calpain inhibitor, apoptosis 
increased significantly.56  Thus, this could be considered as a target for affecting 
VSMC apoptosis.  In general, changing the rate of apoptosis of VSMCs in an 
atheroma could be a potential method for modulating plaque stability. 
 
Proliferation 
VSMC proliferation is a key step in atherogenesis, and a plaque with high 
VSMC content is generally more stable and therefore less likely to initiate a 
clinical event.  Several reports suggest that cyclic strain promotes proliferation in 
VSMCs.74, 88  However, some work suggests that cyclic strain inhibits VSMC 
proliferation.57  As with apoptosis, VSMC phenotype also affects the proliferative 
response to cyclic strain.  Tock, et al., showed that VSMCs isolated from fetal 
rats demonstrated more proliferation in response to cyclic strain (~2.5-fold 
increase over no strain controls) compared to VSMCs from adult rats, which 
showed no significant proliferation.58  Interestingly, in cultured venous VSMCs, 
mechanical stretch has been shown to upregulate insulin-like growth factor-1 and 
its receptor, which, in turn, enhanced VSMC proliferation through PI3K.  This 
revealed a novel pathway underlying the neointima formation observed when 
veins are exposed to arterial biomechanical stress in coronary artery bypass 
grafts.59  Interestingly, cyclic strain in rat VSMCs has been shown to block 
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proliferation by inhibiting notch signaling.91  Finally, it should be noted that 
mechanotransduction through integrins have a potent ability to effect VSMC 
proliferation; VSMC proliferation is promoted by cyclic strain in a mechanism 
which is dependent upon plating on specific substrates and binding through 
specific integrins.  Wilson, et al., showed that the increased proliferation of rat 
VSMCs in response to cyclic strain could be partially abrogated by plating the 
cells on collagen rather than fibronectin or vitronectin (though plating on collagen 
did not completely abolish the proliferative phenotype), by blocking binding to 
fibronectin, or by blocking the fibronectin-binding integrins αvβ3.60  Venous 
VSMCs from mice cultured on collagen increase proliferation in a PI3K-
dependent manner by about 2-fold when exposed to cyclic strain for 48h.59  
However, when rat VSMCs were cultured up to 10 days following cyclic strain, 
they demonstrated a decrease in proliferation.91  
 
Phenotype 
VSMC phenotype (either synthetic or contractile) is known to be mediated by 
cyclic strain.  Albinsson et al., stretched mouse portal veins ex vivo and showed 
that those tissues under strain turned on transcription of several genes 
associated with the contractile phenotype.  This was been shown to be 
dependent on increased actin polymerization with strain, which was related to 
signaling through Rho.93  Expression of smooth muscle α-actin in rat aortic 
VSMCs is enhanced by cyclic strain by 2-3-fold.  This was shown to be 
dependent up on signaling through JNK and p38.58  Interestingly, another group 
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using a different stress model demonstrated that VSMCs degrade smooth 
muscle α-actin when exposed to high arterial-like strain, but to a lesser degree in 
low venous-like pressure.  However, they also implicated a role for p38 in this 
process.61  Finally, another group demonstrated a requirement for p38 in stress-
mediated phenotype modulation, showing that a strain-induced increase in a-
actinin could be ablated using a p38 inhibitor.  Furthermore, they also showed 
that the increase in α-actinin and other markers of VSMC differentiation could be 
altered by changing strain frequency, such that the expression was highest at 
1Hz, but dropped at 2Hz.62 
 The study of VSMCs has revealed a great deal of information into the role 
of biomechanical stress, particularly cyclic strain, in normal smooth muscle cell 
biology.  It also opens a window into understanding the role of VSMCs in the 
pathogenesis of mechano-sensitive diseases such as atherosclerosis.   
 
SPRR3 
Recent work from our laboratory has identified SPRR3 as a mechanically-
responsive protein.  The study of this protein has revealed that it is an exemplary 
model of many of the mechanisms described above. 
SPRR3 is a member of the family of Small Proline-Rich Repeat proteins, 
consisting of members that all possess glutamine- and lysine-rich head and tail 
domains and a proline-rich core.  The flexible core domain is believed to impart 
to tissues an increased ability to stretch while the head and tail domains provide 
anchorage to other proteins.  For example, SPRRs makes up 18% of the total 
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protein in the highly flexible mouse forestomach epithelium, but only 8% in the 
less elastic epidermis.95, 96  Although SPRR proteins have been identified in 
VSMCs, cardiomyocytes, lungs, and uterine epithelia, the SPRRs have primarily 
been studied in the context of their association with the cornified envelope (CE) 
in stratified epithelium.97-100  The CE is a 10-15nm thick proteinaceous structure 
located just inside the plasma membrane of stratified epithelial cells, such as 
terminally differentiated keratinocytes in the skin.  The CE is a barrier against the 
chemical and mechanical assaults frequently experienced by the tissues in which 
it is found, such as the epidermis and esophageal epithelium.101, 102  The 
architecture of the SPRRs is believed to play a central role in the function of the 
CE, as the N- and C-terminal domains are covalently bound by 
transglutaminases (TGases) through ε-(γ-glutamyl)lysine isopeptide bonds to 
other SPRRs and large structural CE members, such as loricrin and involucrin.63  
It is believed that the central core of SPRR3 has virtually no secondary structure, 
a vital characteristic in its function as a flexible cross-bridge between its binding 
partners.103, 104  As illustrated in Figure 1-4, the central domain of SPRR3 allows 
the protein to expand significantly upon force application at either end.  However, 
the function of members of the SPRR family outside the context of the CE is very 
poorly understood.   
Our laboratory recently identified SPRR3 in the vasculature by using 
microarray analysis to compare aorta versus vena cava, in which a group of 
genes was recognized as being highly expressed in large arteries, but in low or 
undetectable levels in large veins.64  These genes, one of which was SPRR3, 
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Figure 1-4 
 
 
Figure 1-4 
Members of the SPRR family of proteins share a unique architecture, 
with TGase substrate domains at the N- and C-termini and a highly flexible 
central domain (a).  As stress is applied to either end of the protein, the proline-
rich central domain can expand (b).  When an SPRR protein is covalently bound 
to another protein at the N- and/or C-termini, the SPRR can act as an expansion 
unit, allowing the protein complex to extend when pulled upon by biomechanical 
stress (c).   
Candi, et al.  Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40.  
c 
a 
b 
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had not previously been studied in the vasculature, though they were all known 
components of the CE.  Interestingly, immunohistochemistry revealed that 
SPRR3 expression was restricted to VSMCs in areas of atherosclerosis in 
human arteries, but not in healthy vasculature (Figure 1-5).64   
The fact that SPRR3 is known to play a role in adaptation to 
biomechanical stress in stratified epithelium, and that our lab found SPRR3 
expression in the vasculature limited to regions of altered stress 
(atherosclerosis), lead us to hypothesize that SPRR3 in VSMCs is regulated by 
biomechanical stress.  Furthermore, recent work from the laboratory of Dr. 
Kenneth Chien implicated another member of the SPRR family, SPRR1a, as 
being turned on as an adaptive response to biomechanical stress.  Pradervand, 
et al., showed that in cardiac tissue SPRR1a is induced in response to ischemic 
and biomechanical stress, and pointed to a possible cardioprotective role of 
SPRR1a.99   
In light of these data, we decided to pursue a mechanical role for SPRR3 
expression in VSMCs.  As will be discussed in more detail in a later chapter, we 
have established that SPRR3 is regulated by cyclic strain in VSMCs.  Moreover, 
we showed that this regulation is dependent upon mechanosensing by integrin 
α1β1 through binding type I collagen.  This finding explains why SPRR3 
expression is restricted to VSMCs within atheromas and is not found in healthy 
arteries; α1β1 expression is limited to the atherosclerotic plaque and is not found 
in other VSMCs.43  This study is one of few reports showing distinct gene 
regulation downstream of mechanical stress on integrins.   
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Figure 1-5: 
 
Figure 1-5 
SPRR3 expression in the vasculature is limited to atheromas.  
Immunoreactivity to SPRR3 is detected extensively in atheromatous regions of 
various arteries, including the aorta (a), iliac artery (b), and renal artery (c).  
However, expression of SPRR3 is not detected in venous tissue, as it is relatively 
resistant to atherosclerotic development. 
Young, PP, et al., Circulation, 2005 
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 The study of the effects of biomechanics on the vasculature, particularly in 
cases of vascular pathology, is an area still ripe for exploration.  The molecular 
changes arising from biomechanics on VSMCs within an established atheroma 
remain largely unknown, particularly as the local microenvironment of the plaque 
changes throughout plaque development and progression.  A better 
understanding of the VSMC response to stress within the atherosclerotic milieu 
will promote the development of better detection and treatment options for 
atherosclerosis.   
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CHAPTER II 
 
BIOMECHANICAL STRESS INDUCES NOVEL ARTERIAL INTIMA-ENRICHED 
GENES:  IMPLICATIONS FOR VASCULAR ADAPATION TO STRESS1
 
 
Introduction 
Blood flowing through the vasculature exerts a significant force on the 
cells of the arteries resulting in biomechanical stress: cyclic and static strain is 
produced as blood pressure pushes against the vessel wall in systole and 
diastole, respectively, and shear stress as the blood flows through the lumen 1, 65.  
However, veins exist in a low pressure environment and are less subject to such 
forces 2, 66.  When veins are arterialized and subjected to a high-stress 
environment, such as when the saphenous vein is used as a coronary artery 
bypass graft (CABG), the primary response is extensive fibrointimal hyperplasia 
(FIH) followed by fibrosis and atherosclerosis that may eventually lead to 
complete graft failure 67, 68.  Within one year of surgery, 10-15% of grafts are 
occluded; within 10 years 70% of grafts exhibit some FIH, and over half of those 
contain lesions large enough to cause occlusion 69, 70.  Vascular smooth muscle 
cells (VSMCs) are a major constituent of the vascular wall and are key cells in 
neointimal lesions in grafted veins and atherosclerosis 71.   
                                                 
1 This chapter has been adapted from the paper: Biomechanical Stress Induces Novel Arterial 
Intima-Enriched Genes:  Implications for Vascular Adapation to Stress.  Pyle AL, Li B, Maupin 
AB, Guzman RJ, Crimmins DL, Olsen S, Atkinson JB, Young PP: Cardiovascular Pathology, In 
Press 
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We previously identified a group of functionally related genes that we call 
the arterial intima-enriched (AIE) genes based on expression that is limited to the 
intimal VSMCs of large arteries, but not veins 64, 72.  The AIE genes include 
sciellin, periplakin, Small Proline-Rich Protein 3 (SPRR3), galectin 7, and 
plakoglobin.  These gene products have been previously characterized in 
stratified epithelia where they contribute to the ability of the tissues to withstand 
chemical and biomechanical stresses.  Specifically, these proteins are 
components of the cornified envelope (CE), a 10-15 nm thick highly cross-linked 
structure just inside the plasma membrane of stratified epithelial cells such as 
keratinocytes 73.  Of particular interest to this study are sciellin, periplakin, and 
SPRR3, each of which has a different function in the CE.  Sciellin contains a core 
of conserved repeats and a unique proline-rich N-terminal domain that are 
proposed to serve a structural role.  Furthermore, it possesses a C-terminal LIM 
domain that is believed to be a protein-interaction domain, possibly bestowing a 
scaffolding function on sciellin 74-76.  Periplakin, a member of the plakin family of 
proteins, is enriched in desmosomes where it acts as a mediator of intermediate 
filament assembly 77, 78.  Small proline-rich protein 3, or SPRR3, is cross-linked 
by transglutamination to other CE members, thereby potentially serving as a 
flexible linker of structural proteins in the CE.  SPRR3 is hypothesized to have a 
highly flexible core of proline-rich repeats, the most flexible of the SPRR family, 
that confers elasticity on the CE 79, 80.   
Because arteries are under considerably greater cyclic strain than veins, 
we hypothesized that at least a subset of the AIE genes are regulated by cyclic 
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strain in the arteries 81.  We examined their distribution and expression by 
immunofluorescence in post mortem samples of arterialized saphenous CABGs 
and mRNA transcript levels in an in vitro model system of cyclic strain.  The 
results of this study provide the novel finding that VSMCs up-regulate the 
transcripts of the structural proteins sciellin, periplakin, and SPRR3 in response 
to prolonged biomechanical stress.  These findings shed new light on the 
response of VSMCs to biomechanical stress. 
 
Methods 
 
Cell Culture and Biomechanical Stress: 
We isolated VSMCs from excess human aortic tissue from heart explants.  
Briefly, the vessels were cleaned of all connective tissue and cut longitudinally to 
expose the lumen, which then was scraped to remove the endothelium.  The 
vessel wall was peeled apart to expose VSMCs on both surfaces.  These were 
then cut into 1 cm square pieces and placed smooth muscle-side down in 
SmGM2 (Clonetics) and held in place by wire mesh.  Outgrowths of cells derived 
from the explants were expanded.  This resulted in a mixed population of cells 
from both the media and intima.  After one passage, co-immunocytochemistry 
was performed with both anti-smooth muscle alpha actin (1:1000, Sigma), anti-
smooth muscle myosin heavy chain (1:250, Abcam), and anti-vonWillebrand 
factor (1:200, Dako).  Cells were only used for experiments when cultures were 
95%-100% smooth muscle alpha actin and smooth muscle myosin heavy chain 
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positive and vonWillebrand Factor negative.  Cultures were maintained in 
SmGM2 and used between passages 4-9.   
 Cells were exposed to cyclic strain as follows.  Cells were plated on 
collagen I coated Flex I elastomer-bottom plates or Flex II solid plates, as control, 
(Flexcell, Int.) and exposed to cyclic strain with 15-20% elongation for 12, 24, 48 
and 72 hours (60 cycles/min) 47, 82.  One hour prior to starting strain, media was 
changed to 10% FBS/DMEM with antibiotics.  Following strain application, cells 
were washed twice with PBS and harvested in Trizol for RNA extraction, or fixed 
for immunofluorescence.  Cyclic strain experiments were performed a minimum 
of three times with cells from two independent cell isolations.   
 
Reverse Transcription and Semi-Quantitative RT-PCR: 
 RNA from VSMCs was isolated with Trizol (Invitrogen) following the 
manufacturer’s instructions and quality confirmed by an A260/280 ratio >1.9.  Semi-
quantitative PCR analysis was performed as previously described 64, 83.  Briefly, 
1ug RNA was used for cDNA synthesis using iScript cDNA synthesis kit (Bio-
Rad).  The cDNA was then used for semi-quantitative PCR using SYBR-green iQ 
PCR supermix and run in an iCycler Real-Time PCR thermal cycler (Bio-Rad).  
Primer sequences and conditions for use can be found in Table 2-1.  All 
transcript levels were set relative to the level of 18S RNA present in each 
sample.  The results are presented as fold change from non-stressed samples.  
Results are shown from three independent experiments, each of which was 
analyzed in triplicate. 
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 Immunofluorescence: 
 Sections from formalin-fixed, paraffin-embedded human saphenous vein-
derived CABG grafts and control non-arterialized saphenous veins were stained 
as described 64.  The duration of the bypass grafts used in our studies was 12-72 
months post-implantation and were obtained from both male and female patients.  
These grafts were from individuals who received bypass grafts for ischemic heart 
disease.  Based on our analysis of graft morphology, grafts that demonstrated 
significant intimal hyperplasia and/or atherosclerosis were used for further study.  
Human aortic VSMCs grown on elastomer membranes were fixed for 20 min at 
room temperature with 4% paraformaldehyde, followed by permeabilization with 
0.4% Triton in PBS.  Subsequently, the membranes were cut out of the dishes 
and cut into smaller wedges so that each membrane could be stained for several 
different proteins.  Each membrane wedge was blocked for 1 hr with 10% goat 
serum and primary antibody applied in 3% goat serum overnight at 4oC.  The 
following primary antibodies were used:  polyclonal SPRR3 (1:400, Alexis 
Biochemicals), polyclonal sciellin (1:400, the kind gift of Dr. Howard Baden, 
Department of Dermatology, Cutaneous Biology Research Center, Harvard 
Medical School, Massachusetts General Hospital, Boston, MA84), polyclonal 
periplakin (1:100, generated against R1729-G1754.  The antibody was affinity 
purified and recognized a single band of 195 kDa from human skin protein lysate 
by western blot 85, 86), monoclonal plakoglobin (1:200, Sigma), polyclonal galectin 
7 (1:400, Bethyl Laboratories), monoclonal vimentin (1:100, Dako), monoclonal 
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Golgin 97 (1:100, Molecular Probes), monoclonal Prohibitin (1:100, Calbiochem), 
and monoclonal protein disulfide isomerase (PDI) (1:100, Affinity BioReagents).  
The slides/membranes were rinsed twice with PBS and incubated in either goat 
anti-rabbit-Cy3, goat anti-mouse-alexa 488 (1:200, Molecular Probes); selected 
membranes were co-stained with FITC- or rhodamine-labeled phalloidin (1:40, 
Molecular Probes).  Finally, the samples were counterstained with DAPI and 
mounted as described 64, 87.  As a negative control, parallel staining was carried 
out with secondary antibody alone.  Slides were viewed under a Zeiss Axioplan 
microscope (Carl Zeiss MicroImaging), and analyzed with MetaMorph Imaging 
system (Molecular Devices).  The staining and co-localization was confirmed by 
fluorescent confocal microscopy using a Zeiss upright LSM510 confocal 
microscope and the images were analyzed using LSM Image Browser.   
 
Statistical Analysis: 
 CABG data was analyzed by chi squared analysis and the stress data 
using a one-way ANOVA with Newman-Keuls Comparison analysis.  Error bars 
represent ± standard deviation.  p<0.05 was considered statistically significant. 
 
Results 
Sciellin and Periplakin are Accumulated in Coronary Artery Bypass Grafts 
 Saphenous veins are commonly used to bypass occluded coronary 
arteries 68.  Upon introduction into the arterial circulation, the saphenous vein 
graft can experience up to 10-fold increase in biomechanical forces and therefore 
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serves as an ideal in vivo model to test the hypothesis that the AIE genes are 
regulated by biomechanical stress 81.  Cadaveric paraffin-embedded saphenous 
vein CABGs were analyzed by indirect immunofluorescence with antibodies 
against sciellin, periplakin, SPRR3, plakoglobin, and galectin 7.  The arterialized 
explants all contained extensive fibrointimal hyperplasia with varying degrees of 
thrombosis and plaque formation while the non-arterialized saphenous veins 
displayed only minimal intimal hyperplasia (Figure 2-1a).  In the absence of 
neointima formation, non-arterialized veins were not recognized by any of the 
antibodies (b-f, right panels, Table 2-2, n=4 non-arterialized veins).  However, 
when arterialized veins were examined for the AIE proteins, greater than 80% 
and 50% were positive for sciellin and periplakin respectively (Table 2-2, n=17 
(sciellin) and n=26 (periplakin) and Figure 2-1b,c, left panels).  However, 
consistent with our previous observations, SPRR3 expression was restricted to 
atherosclerotic plaques within grafts (Figure 2-1d) 64.  Furthermore, while 
plakoglobin and galectin 7 stained positive in some arterialized veins (but were 
negative in non-arterialized saphenous veins), the number of positive grafts was 
not statistically significant (Table 2-2, n=29 (plakoglobin and galectin 7), Figure 2-
1e,f).  These findings indicate that sciellin and periplakin protein accumulated in 
vivo in intimal VSMCs following arterialization.  Additionally, our previously 
described finding of atheroma-associated SPRR3 expression in arteries has 
been extended to atheromas present in arterialized saphenous vein grafts 64.   
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Figure 2-1 
 
Figure 2-1 
AIE proteins are accumulated in arterialized veins. 
Cadaveric saphenous vein CABGs and non-arterialized saphenous veins were 
examined for expression of sciellin (b), periplakin (c), SPRR3 (d,arrowheads), 
galectin 7 (e), and plakoglobin (f) by indirect immunofluorescence.  Extensive FIH 
is seen in the arterialized veins (arrows), but to a lesser extent in non-arterialized 
veins, as seen in H&E stained sections (a).  L indicates lumen.  Scale bar is 80 
µm (a, d) and 40 µm (b, c, e, f). 
 
36
 
 
 
 
 
Table 2-2:  Quantitation of CABG staining. 
Control vein is non-arterialized saphenous vein; CABG is saphenous vein 
coronary artery bypass graft.  Each CABG counted per group represents a 
unique graft from different individuals. 
 
 
 
  Control Vein CABG p-Value 
Sciellin 0/4 (0%) 14/17 (82.4%) <0.0002 
    
Periplakin 0/4 (0%) 14/26 (53.8%) <0.05 
    
Galectin 7 0/4 (0%) 5/29 (17.2%) >0.3 
    
Plakoglobin 0/4 (0%) 2/29 (6.9%) >0.3 
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Sciellin, Periplakin, and SPRR3 are upregulated by cyclic strain in vitro 
 Because increased biomechanical stress during arterialization is an 
important stimulus for intimal hyperplasia formation, we hypothesized that 
expression of the AIE genes was upregulated in response to biomechanical 
stress 71, 81, 88.  To test this, VSMCs were isolated from aorta samples from two 
individuals.  The cells were then exposed to cyclic strain by applying a computer-
controlled vacuum to elastomer-bottomed plates (with 15-20% stretch).  Previous 
studies have measured the distention of human arteries at 18% elongation, and 
therefore a similar level of cyclic stretch was applied to the cells in vitro 89, 90.  
This was followed with analysis by qRT-PCR of the mRNA transcript levels of two 
control genes, MMP-2 and elastin, which have been shown to be upregulated in 
VSMCs by biomechanical stress, and the six AIE genes 35, 36.  The VSMCs were 
responsive to cyclic strain at 48 h as demonstrated by the upregulation of MMP-2 
and elastin transcripts by 2.09±0.366-fold (p=0.035, n=4) and 8.88±0.028-fold 
(p=0.00162, n=4), respectively (Figure 2-2a).  Analysis of the AIE genes revealed 
upregulation of sciellin, periplakin, and SPRR3 at 48 and 72 h of cyclic strain 
(Figure 2-2b,c,d).  Sciellin transcripts increased by 2.47±0.926-fold (p≤0.05, n=4) 
and 4.67±0.421-fold (p≤0.05, n=3), periplakin by 2.77±1.30-fold (p≤0.05, n=4) 
and 1.56±0.028-fold, and SPRR3 by 2.1±0.18-fold (p≤0.05, n=3) and 4.95±0.029-
fold (p≤0.05, n=3) after cyclic strain for 48 and 72h, respectively.  However, the 
data were not statistically significant for plakoglobin, envoplakin, and galectin 7 
transcripts (Figure 2-2e,f,g).  These data suggest that sciellin, periplakin, and 
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Figure 2-2 
 
Figure 2-2 
AIE gene expression regulation by biomechanical stress. 
Real time RT-PCR revealed changes in transcript levels.  (a) Fold change of 
MMP-2 and elastin after 48h.  Sciellin transcripts increase significantly after 
prolonged cyclic strain of 48h and 72h (b), as do periplakin and SPRR3 (c,d).  No 
statistically significant increase was seen for galectin 7, plakoglobin, or 
envoplakin (e, f, g).  *p≤0.05; NS: No Cyclic Strain. 
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SPRR3 are all transcriptionally responsive to prolonged exposure to cyclic strain 
in human VSMCs.   
 
Arterial Intima Enriched proteins had unique expression patterns in VSMCs. 
Previous studies have shown that the location of a protein in VSMCs can 
be modulated in response to biomechanical stress 91-94.  Therefore, subcellular 
localization of sciellin, periplakin, SPRR3, galectin 7, and plakoglobin was 
studied by indirect immunofluorescence in VSMCs with or without 72h of cyclic 
strain.  Galectin 7 and plakoglobin were only faintly detectable and did not 
change cellular localization with cyclic strain when compared to unstrained 
controls (data not shown).  Sciellin, however, displayed a diffuse cytoplasmic and 
peri-nuclear expression pattern (Figure 2-3a) that did not change with stress.  
Sciellin failed to co-localize with other cellular elements, such as filamentous 
actin (Figure 2-3b), the intermediate filament vimentin, tubulin, the golgi 
apparatus (as detected by an antibody against golgin 97), or the endoplasmic 
reticulum (as detected by an antibody against PDI) (data not shown).  Therefore, 
sciellin distribution did not correlate with any major structural elements within the 
cell.  A previous study demonstrated that periplakin associates with vimentin in 
keratinocytes, establishing its role as a structural protein 77, 95.  Not surprisingly, 
periplakin co-localized with vimentin in VSMCs, but no change was noted with 
the addition of cyclic strain (Figure 2-3d).  Periplakin did not co-localize with actin 
or tubulin (data not shown).  Finally, SPRR3 was detected in a peri-nuclear 
region in cells without strain, whereas it was more widely distributed through the 
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Figure 2-3 
 
Figure 2-3 
Localization of AIE gene products in VSMCs by indirect 
immunofluorescence.  Sciellin (red) in a diffuse cytoplasmic and peri-nuclear 
pattern (a), does not co-localize with actin (FITC-phalloidin, green) (b).  
Secondary-only control (c).  Periplakin (red) co-localized with vimentin (green) 
(co-localization—arrowheads) (d).  SPRR3 (red) co-localizes with golgi marker 
(green) in the absence of cyclic strain (e) but is found in a cytoplasmic network 
after 72h stress (f).  Nuclei are stained blue by DAPI.  Scale bar is 20µm. 
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cytoplasm in a reticular pattern after 72h of cyclic strain.  In unstrained cells, 
SPRR3 co-localized with the golgi apparatus (Figure 2-3e).  However, after 
strain, the cytoplasmic distribution of SPRR3 did not co-localize with our selected 
golgi-, endoplasmic reticulum- or mitochondria-marker proteins.  It also failed to 
co-localize with F-actin, vimentin, or tubulin (Figure 2-3f, data not shown).  For all 
of these experiments, the secondary antibody-only negative control was negative 
(Figure 2-3c).   
 
Discussion 
The differences in the molecular profiles of adult arteries and veins are not 
well known, despite the established functional, morphological, and pathological 
differences 96.  We previously identified a group of genes that are expressed in 
arterial intimal smooth muscle cells, the arterial intimal enriched (AIE) genes 64.  
This study demonstrated that expression of a subset of the AIE genes, 
specifically sciellin and periplakin, was increased in arterialized human veins 
(CABGs), and their transcripts, as well as that of SPRR3, which has an 
expression pattern limited to atherosclerotic plaques, were upregulated by cyclic 
strain. 
The manner by which the AIE genes are regulated by cyclic strain remains 
unclear.  The majority of studies that have examined signaling molecules in 
VSMCs in response to stress have focused on early time points (5min to 24h), 
whereas the effects on sciellin, periplakin, and SPRR3 were detected after 48h 
cyclic strain 81, 82, 92.  Our finding that the expression of these genes was 
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increased following prolonged exposure to cyclic strain (48 to 72h) may provide 
better insight into the mechanisms of VSMC adaptation in vivo to long-term 
mechanical stress 88, 97.  Furthermore, in light of the fact that the structural effect 
of cyclic strain in VSMCs is not completely understood, it is of particular interest 
that previous work in keratinocytes that has defined sciellin, periplakin, and 
SPRR3 as structural proteins is of interest 35, 91.  Modulation of other structural 
proteins by cyclic strain in VSMCs has been previously shown.  Regulation of 
extracellular matrix proteins such as tenascin C and elastin by cyclic strain has 
been demonstrated 35, 91.    Zyxin, a focal adhesion protein, has been shown to 
translocate from focal adhesions to the nucleus where it is required for 
expression of certain mechanosenitive genes 91.  Thus, this study further 
develops the notion that cyclic strain regulates cellular function through the 
regulation of structural proteins, specifically sciellin, periplakin, and SPRR3.  
These alterations may have important implications during vascular adaptation 
to arterialization.  
The function of the AIE genes in VSMCs remains unclear, but studies of 
AIE genes in stratified epithelia, where they serve as structural molecules, may 
yet shed light on their function in the vasculature.  Sciellin was initially 
characterized in a screen of antigens generated from human keratinocyte CE 
fragments as a highly insoluble CE precursor and transglutaminase substrate 98.  
Subsequently, sciellin was shown to contain a proline-rich N-terminal domain, a 
central 16 repeat glutamine- and lysine-rich motif—the transglutaminase 
substrate—and a C-terminal LIM domain 74, 76.  LIM domains, which are protein-
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interaction motifs, have been demonstrated in other proteins associated with the 
cytoskeleton and biomechanical stress in VSMCs 91, 99.   Notably, there was no 
phenotype observed in sciellin knockout mice76.  A yeast two-hybrid screen 
revealed that sciellin in keratinocytes interacts with vitamin D-upregulated protein 
(VDUP), an endogenous inhibitor of thioredoxin 84, 100.  Interestingly, VDUP 
expression has been shown to be regulated by biomechanical stress in 
cardiomyocytes and by oxidative stress in VSMCs, resulting in altered 
thioredoxin activity 100-102.  The relationship between VDUP and sciellin as well as 
VDUP and biomechanical stress implicates a possible role for sciellin and VDUP 
together in our system.   
Periplakin has also been identified as a CE precursor.  It is found in 
desmosomal plaques and interdesmosomal networks where it has been shown 
to associate with keratins and vimentin, and has been hypothesized to act as a 
scaffold for intermediate filament assembly 77.  Thus, our finding that periplakin 
co-localizes with vimentin in VSMCs is consistent with the data obtained from 
studies in keratinocytes.  While the periplakin knockout has no obvious 
phenotype, deletions of other desmosomal proteins in mice, such as plakoglobin 
and desmoplakin, are lethal in utero with major defects in heart muscle resulting 
from an inability to function under biomechanical stress 78, 103, 104. 
SPRR3 is a member of the small proline rich protein family that all contain 
glutamine- and lysine- rich head and tail domains and a proline rich core.  In 
SPRR3, the head and tail domains are substrates for transglutamination, while 
the proline-rich central domain is highly flexible.  This structure has been 
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correlated to a function as a cross-bridging protein, such that SPRR3 is 
transglutaminated on either end to provide mechanical resistance, while the 
flexible central domain confers elasticity to the protein complex, and thus the 
tissue 80.  Therefore, we expected to find SPRR3 associated with structural 
cellular elements, such as the cytoskeleton, but were surprised to see its 
association with the golgi apparatus.  Thus, the role of SPRR3 in isolated VSMCs 
remains a mystery.  Interestingly, another member of the SPRR family has 
recently been implicated in cardiovascular physiology.  Pradervand, et al., 
showed that SPRR1a is induced in cardiac tissue in response to ischemic and 
biomechanical stress and pointed to a possible cardioprotective role 105.   
 This work holds implications for a variety of vascular pathologies.  For 
example, the role of the AIE proteins in adaptation to biomechanical stress could 
be related to disease pathogenesis.  Data in Chapter IV will demonstrate that 
SPRR3 can regulate VSMC proliferation, which could underlie VSMC 
proliferation in an atheroma and thus disease progression.  Sciellin and/or 
periplakin could affect cellular proliferation and survival in a similar manner to 
promote vein graft neo-intima formation, perhaps by affecting cellular stability in 
the face of biomechanical stress.  Future work could elucidate the means of 
function for the AIE genes in VSMCs, as well as establishing a pathway for their 
regulation by cyclic strain.  The following two chapters will show the work to 
establish a detailed mechanism for SPRR3 regulation by cyclic strain, as well as 
work trying to determine the function of SPRR3 in VSMCs.   
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CHAPTER III 
 
Regulation of the atheroma-enriched protein, SPRR3, in vascular 
smooth muscle cells through cyclic strain is dependent on integrin 
α1β1/collagen interaction2
 
As shown in Chapter II, we have demonstrated that the AIE genes sciellin, 
periplakin, and SPRR3 are all regulated by biomechanical stress, though the 
exact mechanism by which the regulation occurs remains unclear.  Here we 
illustrate the means by which SPRR3 regulation occurs through cyclic strain.  
 
Introduction 
Atherosclerosis is known to arise in regions of the vasculature subjected 
to altered hemodynamic stress.20  Recent studies have shown that 
biomechanical stress caused by altered flow not only leads to atherosclerosis, 
but atherosclerosis itself alters local biomechanics.106, 107  New, more sensitive 
technological innovations, such as intravascular ultrasound, have revealed that 
even early atherosclerotic lesions significantly affect vessel compliance.106, 108  
Studies have considered changes in VSMCs gene expression in other vascular 
pathologies,48, 109 however little is known about how locally altered biomechanics 
affect VSMCs within the context of atheromas.   
                                                 
2 This chapter has been adapted from the paper: Regulation of the atheroma-enriched protein, 
SPRR3, in vascular smooth muscle cells through cyclic strain is dependent on integrin 
alpha1beta1/collagen interaction.  Pyle AL, Atkinson JB, Pozzi A, Reese J, Eckes B, 
Davidson JM, Crimmins DL, Young PP: Am J Pathol 2008, 173:1577-1588 
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In a previous study we showed that the protein SPRR3 is highly expressed 
in advanced atheromas of human arteries.64  SPRR3 is a member of the family of 
Small Proline-Rich Repeat proteins, consisting of members that all possess 
glutamine- and lysine-rich head and tail domains and a proline-rich core.80  The 
flexible core domain is believed to impart to cells an increased ability to stretch 
while the head and tail domains are anchored to other proteins80, 110.  Many 
members of the SPRR family of proteins serve as constituents of the cornified 
envelope, which is an insoluble protein complex formed under the plasma 
membrane in the uppermost layers of stratified squamous epithelium.98 75 111  
The cornified envelope plays a major role in the mechanical and barrier 
properties of these tissues.79  A recent study identified other SPRR members as 
stress-inducible, cardioprotective proteins.105  Both SPRR1a and 2a/b were 
identified as downstream targets of gp130 signaling that are strongly induced in 
cardiomyocytes in response to biomechanical stress.105  Ectopic overexpression 
of SPRR1a protected cardiomyocytes from ischemic injury both in vivo and in 
vitro.105   
Many proteins have been implicated in mechanosensing in VSMCs, 
especially integrins.65, 112-114  Integrins are transmembrane adhesion receptors 
that primarily bind extracellular matrix (ECM).115  They function in a non-
covalently bound heterodimer composed of an α and a β subunit26.  Studies have 
shown that chronic stretch and hypertension increase ECM production, as well 
as integrin expression on VSMCs.35, 116, 117  Current concepts suggest that 
mechanical signals are transmitted from integrin-ECM binding sites to the 
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cytoskeleton and hence to other transduction molecules in the cytoplasm and 
nucleus.118 
The recognized biomechanical disruptions around atherosclerotic plaques 
and the putative role of SPRR family members in epidermal and possibly cardiac 
biomechanics led us to test the hypothesis that SPRR3 gene expression was 
regulated by mechanical stress in VSMCs.  This would represent a novel 
component of the molecular adaptation of VSMC to biomechanical alterations 
within atheromas.  We investigated the mechanism of transcriptional regulation of 
SPRR3 by cyclic strain (CS) and implicated signal transduction via integrin α1β1 
and collagen in SPRR3 gene regulation in VSMCs.   
 
Methods 
Materials: 
Antibodies: anti-hSPRR3 (clone 4a; Alexis Biochemicals, San Diego, CA), 
anti-vWF (Dako, Glostrup, Denmark), anti-mouse integrin α1 subunit (clone Ha 
31/8; BD Pharmingen, San Diego, CA), anti-mouse integrin α2 subunit (clone 
Ha1/29; BD Pharmingen), anti-β-actin (clone AC-15; Sigma-Aldrich, St. Louis, 
MO), anti-smooth muscle myosin heavy chain (clone 1G12; Abcam, Cambridge, 
MA), and anti-smooth muscle α-actin (α-SMA; clone 1A4, Sigma-Aldrich).  We 
generated and affinity purified a polyclonal Armenian hamster anti-mouse 
SPRR3 against the peptide spanning amino acids V45-P56 of mSPRR3.  By 
immunoblot, this antibody recognized a 30 kDa band from mouse esophagus 
lysate as well as COS-7 cells overexpressing SPRR3 (Image Clone ID:  
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4288753).  This band was competed away by preincubation with the immunizing 
peptide (Figure 3-2a).   
Animals:  
All animals and procedures were carried out in accordance with the 
Vanderbilt Institutional Animal Care and Use Committee.  C57Bl/6 (wildtype, 
WT), H-2Kb-tsA58119 (Tag; colony maintained by J.R. at VUMC), and α1-
integrin120 and α2-integrin121 subunit null mice were sacrificed between 2-3 
weeks of age by cervical dislocation and their thoracic aortas were harvested for 
VSMC isolation.  ApoE-/- and syngeneic Bl/6 WT control mice (gift of Dr. A. 
Hasty,122 Vanderbilt University) were maintained on regular chow diet and 
sacrificed at 6 months of age for histologic evaluation of proximal aorta lesions.  
Cell Culture: 
Protocols involving human tissues were reviewed by the Vanderbilt 
Institutional Review Board. Human (h)VSMCs were isolated from excess aortic 
tissue from heart explants (in generous collaboration with Dr. Davis Drinkwater 
and Mr. Paul Chang).  VSMCs were isolated from n=4 donors.  The vessels were 
cleaned of adventitia, cut longitudinally, and the lumen was scraped to remove 
the endothelium.  Segments from the media were cut into 0.5 cm2 and cultured in 
SmGM2 media (Lonza, Basel, Switzerland) until outgrowth of cells.  A similar 
procedure was used to obtain VSMCs from mice.  Murine cells were maintained 
in 15% FBS/DMEM/Penicillin/Streptomycin with or without 200pM TGF-β.123  
Each independent isolation of VSMCs was assessed by immunofluorescence 
with anti-smooth muscle α-actin (α-SMA, 1:1000), anti-SM myosin heavy chain 
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(SM-MHC, 1:250), and anti-vWF (1:200).  CS experiments were performed with 
cells that were 95%-100% α−SMA and SM-MHC positive and vWF negative.  
VSMCs were maintained at 37oC in 5% CO2 and used between passages 4-9, 
except immortal Tag-VSMCs, which were culture expanded at 33oC in the 
presence of 10ng/ml interferon-γ and subcultivated for 10 days (5 passages) in 
regular media at 37oC prior to use.124  VSMCs were treated with 75 µg/ml of LDL 
or mildly oxidized LDL in medium containing 1% FBS (kind gift of W. G. Jerome) 
for 48 or 72 hours.125  
Biomechanical Stress Application:  
VSMCs were exposed to CS by plating cells at 1x104 cells/well on Flex I 
elastomer-bottom dishes or control solid Flex II plates (Flexcell Int, Hillsborough, 
NC) and allowed to adhere overnight.  Plates were commercially prepared with 
type I collagen or pronectin F coating.  Uncoated plates were treated with 
100µg/ml poly-L-lysine for 3hr at 37oC.  In some experiments, VSMCs were 
preincubated 1h on ice with 2µg antibody/1x104 cells.  VSMCs were exposed to 
CS with 15-20% elongation for 24 to 72 hours at 1Hz (60 cycles/min) via 
application of a vacuum (15-20 kPa) by a computer-controlled mechanical strain 
unit (Flexercell 2000, Flexcell Int).  All experiments shown were performed a 
minimum of three times. 
VSMCs were exposed to a constant level of shear stress using a cone-
plate viscometer.  Cone angle and rotational velocity were selected to produce a 
steady shear stress at either 5 or 10 dynes for 12 and 24hr (1 dyne = 100mN).  
Following strain application cells were washed with PBS and harvested in Trizol 
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for RNA extraction, in 8M urea buffer for protein, or fixed for 
immunofluorescence. 
Reverse Transcription and Semi-Quantitative (q) RT-PCR: 
 RNA from VSMCs was isolated with Trizol (Invitrogen, Carlsbad, CA) 
following the manufacturer’s instructions, and quality was confirmed by an A260/280 
ratio ≥1.9, as well as clear bands of 28 and 18S rRNA by gel electrophoresis.  
Following isolation, RNA was treated with RNase-free DNase to eliminate 
contaminating DNA and processed with the RNeasy RNA cleanup kit (Qiagen, 
Valencia, CA).  cDNA was generated using iScript cDNA synthesis kit (Bio-Rad, 
Hercules, CA) from 1µg RNA.  The cDNA was then used for real-time PCR using 
SYBR-green iQ PCR supermix and run in an iCycler Real-Time PCR thermal 
cycler (Bio-Rad).  Primer sequences are shown in Table 1.  The average cycle 
threshold from triplicate reactions was used to quantify the relative amount 
mRNA present based on a standard curve.  The differences between samples 
were determined based on the comparative Ct model 83.  Data was compiled by 
calculating ΔΔCt relative to the level of 18S RNA present in each sample.  A 
standard curve composed of serial dilutions of a positive control was run with 
each reaction.  A single amplification product was confirmed by the presence of a 
single band of the correct size by agarose gel electrophoresis, as well as by a 
single peak in a melt curve analysis of the PCR products.  Furthermore, samples 
were only analyzed when the no-template control reaction was negative.  The 
results are presented as average of fold change from non-stressed samples from 
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multiple, independent experiments; PCR analyses from each experiment 
performed in triplicate. 
Immunofluorescence/Immunohistochemistry: 
 Human tissue was obtained from autopsies (post mortem time ranged 
from 2-12 hours) from males and females whose cause of death was not 
vascular related.  Regions were from both proximal and distal large arteries 
(n=38) and large veins (n=8).  Of these, n=12 of the human aortas contained 
primarily early atherosclerotic lesions (fatty streaks and intermediate lesions) and 
n=4 aortas that were histologically normal were analyzed by H&E and SPRR3 
immunohistochemistry.  Histologic analyses were performed by a cardiovascular 
pathologist (Dr. J. Atkinson). Sections from formalin-fixed, paraffin-embedded 
human arteries were stained as described.64  Briefly, the slides were 
deparaffinized and subjected to antigen retrieval in citrate buffer.  The primary 
antibodies recognized human SPRR3 (1:400) and α-SMA(1:1000).  Frozen 
sections of mouse proximal aortas fixed with cold acetone were stained using 
antibodies against mouse SPRR3 (3E9.1; 1:250), α1-integrin subunit (1:100), α2-
integrin subunit (1:200), and/or α-SMA (1:2000) followed by appropriate 
fluorescent-conjugated secondary antibodies.  Human VSMCs grown on 
elastomer membranes were fixed for 20 min at room temperature with cold 
acetone, followed by permeabilization with 0.4% Triton in PBS.  Subsequently, 
the membranes were cut out of the dishes.  Each membrane was blocked for 1 
hr with 10% goat serum and primary antibodies for SPRR3 (1:400), and SM-
MHC (1:20) were applied in 3% goat serum overnight at 4oC and incubated with 
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the appropriate secondary antibodies the following day.  Slides were viewed 
under a Zeiss Axioplan microscope (Carl Zeiss MicroImaging, Thornwood, NY), 
and analyzed with MetaMorph Imaging system (Molecular Devices, Sunnyvale, 
CA).  The staining and co-localization was confirmed by fluorescent confocal 
microscopy using a Zeiss upright LSM510 confocal microscope and the images 
were analyzed using LSM Image Browser (Zeiss).   
Immunoblotting: 
VSMC lysates were harvested by scraping in urea buffer (8M Urea, 75mM 
Tris pH 8.0, 2% SDS, 5% β-mercaptoethanol, protease inhibitors) and 
centrifuged at 10,000xg for 10min at 4oC and the debris pellet discarded.  
Immunoblotting was carried out as described elsewhere.126  Primary antibodies 
used were anti-mouse SPRR3 (3E9.1, 1:1000) and anti-β-actin (1:5000) with 
appropriate HRP-conjugated secondary antibodies.   
Statistical Analysis: 
Statistical analyses were performed using GraphPad Prism5.  All data are 
shown as ± standard error of the mean.  When comparing two samples, a Mann-
Whitney U test was used and for experiments with multiple groups, a non-
parametric Repeated Measures ANOVA with Bonferroni correction was used.  p-
values ≤ 0.05 were considered significant.   
 
Results 
SPRR3 localizes to VSMCs in atherosclerotic lesions.  SPRR3 was detected 
even in early atherosclerosis within subendothelial intimal cells (Figure 3-1a,c).  
We detected specific staining in five out of six fatty streaks and all six 
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Figure 3-1 
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Figure 3-1 
SPRR3 is enriched in VSMCs in human and mouse atheromatous lesions.  
Representative sections from paraffin-embedded tissues of human arteries 
obtained from different individuals containing fatty streaks show SPRR3-positive 
staining (brown) within the affected intima (a, c).  Corresponding regions with 
normal histology from the same vessel (b,d, respectively) are negative. 
Arrowheads designate foam cells.  SPRR3-stained human aortas containing 
advanced atherosclerotic lesions (e-f) show extensive SPRR3 immunopositive 
staining within the fibrous cap (e) and dispersed through the lesion (f).  An H&E 
of the lesion in (e) (inset) is shown with a box denoting the region magnified in 
(e).  The tissue is fractured due to calcification within the atheroma.  No SPRR3-
staining detected within the vessel wall of histologically normal human inferior 
vena cava, nor was it found in the medial VSMCs beneath any of the lesions (j, 
data not shown). The boxed area in (f) corresponds to the region of the vessel 
examined by indirect immunofluorescence for co-staining of SPRR3 (g, red) and 
α-SMA (h, green). (i) Overlay in which co-localization is denoted with 
arrowheads. Note the presence of extracellular SPRR3 which does not co-
localize with DAPI (i, arrows).  Representative H&E stained proximal aortic lesion 
from ApoE-/- (k) and its serial section (l) stained for SPRR3.  Immunopositive area 
coincided with the VSMC-rich fibrous cap (indicated by arrows; (l) is the 
magnification of the boxed area in (k)).  Vessel lumen (L), Lipid-Rich Core (LRC).  
Scale bar = 20µm, 10x objective (a-f, j-k), 40x objective (g-i, l). 
55
  
Figure 3-2 
Figure 3-2 
Validation of SPRR3 antibodies. (a) 3E9.1 recognized a 30kDa band in Cos7 
cells overexpressing SPRR3.  This band was competed away by preincubation 
with the immunizing peptide.  (b)  Positive (Esophagus) and negative (Secondary 
Antibody Only) controls for immunostaining both human and mouse tissue for 
SPRR3. 
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intermediate lesions examined, but not in normal regions within the same vessel 
(Figure 3-1a-d). Extensive SPRR3 immunoreactive areas were identified in all 
advanced atheromas (Figure 3-1e-f).  No specific staining was observed in 
normal veins (Figure 3-1j).  Immunofluorescence was used to co-localize 
expression of SPRR3 and α-SMA, a marker for VSMCs, within a human arterial 
atherosclerotic lesion.127  Numerous areas of co-localization indicated that a 
large number of VSMCs within plaques expressed SPRR3 (Figure 3-1g-i, 
arrowheads).  There was also some evidence of extracellular deposition of 
SPRR3, which may be the result of protein secretion or cell death (Figure 3-1g-i, 
arrows).  SPRR3 staining was also evident in lesions within the smooth muscle 
cell-rich fibrous caps of the proximal aortas of Apo E-/- mice (Figure 3-1k,l).  
Human and murine esophagus were stained in parallel as positive control128 and 
secondary antibodies alone were used as negative controls (Figure 3-2b). 
 
SPRR3 gene expression is regulated by cyclic strain in VSMCs but not by lipids 
or shear stress.  Independent preparations of primary hVSMCs were each 
assessed by immunofluorescence for expression of SM α-actin and SM-MHC 
(Figure 3-3a) to confirm the VSMC phenotype in >90% of the cultured cells prior 
to use in experiments.  Furthermore, we demonstrated co-distribution in hVSMCs 
of SPRR3 with SM-MHC (Figure 3-3b), supporting the role of SPRR3 in 
biomechanics.129, 130  To determine if SPRR3 expression was influenced by 
biomechanical stress when grown on native type I collagen, we measured 
SPRR3 mRNA levels by qRT-PCR in response to cyclic strain (CS) and shear 
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Figure 3-3 
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Figure 3-3 
SPRR3 is regulated by CS in human VSMCs. (a) Primary hVSMC cultures 
expressed both α-SMA and SM-MHC.  (b) SM-MHC (green) and SPRR3 (red) 
co-distributed (yellow, arrowheads).  mRNA levels of SPRR3 (c), elastin (d, 48h), 
MMP2 (e, 48h) after exposure to CS relative to unstrained controls (n=4 
independent CS experiments). Immunofluorescence of representative strained 
and unstrained cells from the same experiment demonstrated clearly increased 
cellular SPRR3 protein expression following 72h CS (f). Shear stress (24h) had 
no effect on SPRR3 transcript levels at either 5 or 10 dynes (g) (n>3 independent 
primary VSMC preps and CS experiments).  Culturing hVSMCs with lipids (h, 
only 48 h data shown) did not induce SPRR3 transcripts over control (n=4 
independent experiments in triplicate). Scale bar = 20µm, 20x objective (a), 40x 
objective (b).  *p≤0.05 
59
stress.  Collagen I was chosen as it is a predominant matrix protein in the arterial 
wall.131  Following CS application for 24-72h, SPRR3 transcript levels were 
increased by 2.1+1.1- and 4.95+0.7-fold after 48 and 72h, respectively, of 
continuous strain as compared to unstrained cells (Figure 3-3c).  As a positive 
control, we assessed concomitant upregulation of the previously studied stress-
sensitive transcripts, elastin and MMP-2 (Figure 3-3d-e).35, 36  Elastin and MMP-2 
transcripts were increased by 5.85+1.8- and 2.11+0.4-fold, respectively, over 
unstrained control VSMC after 48 hours of CS.  By immunofluorescence, SPRR3 
protein levels were shown to increase following 72h CS (Figure 3-3f).  As VSMCs 
are indirectly affected by shear forces89, 132-134, we also investigated whether 
SPRR3 was transcriptionally regulated by shear stress in culture. Human VSMCs 
were exposed to shear stress at either an arterial level of 10 dynes or a venous 
level of 5 dynes for 12 or 24h (Figure 3-3g shows data for only 24 hour).132, 133 
There were no significant changes in transcript levels of SPRR3 following 
application of shear stress.  Since VSMCs within atheromas are exposed to a 
lipid-rich environment, we investigated if SPRR3 expression was influenced by 
lipids.  Levels of SPRR3 were significantly reduced after exposure to oxidized 
LDL (Figure 3-3h), while the addition of either oxidized or unoxidized LDL for 48h 
or 72h (only 48h data shown, Figure 3-3h) hours did not increase SPRR3 
transcript levels in VSMCs. 
Due to the limited availability of primary VSMCs from human aortic 
explants, it was of interest to determine if our results could be recapitulated using 
both mouse primary wildtype VSMCs (WT-VSMC) as well as VSMC lines 
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generated from the transgenic H-2Kb-tsA58 mouse (Tag-VSMC). This mouse 
possesses a heat-labile T-antigen (Tag) expressed behind the mouse major 
histocompatibility complex H-2Kb, which is widely expressed and is further 
inducible by interferon-γ.  Therefore, cells isolated from these animals can be 
conditionally immortalized by growth at a permissive temperature of 33oC and in 
the presence of interferon-γ, but can be returned to normal primary culture-like 
conditions when grown at 37oC.119  As primary cells must be used within 9 
passages, conditionally immortal Tag-VSMCs enabled us to circumvent the 
difficulty of obtaining sufficient numbers for extended analysis.  We confirmed 
that both WT-VSMCs and Tag-VSMCs grown at 37oC expressed a-SMA and SM-
MHC (Figure 3-5).  Both WT and Tag-VSMCs were subjected to CS for 72h and 
both demonstrated statistically significant upregulation of SPRR3 mRNA 
transcript levels between ~2-2.5-fold, respectively (Figure 3-4a, c).  Interestingly, 
both types of murine VSMCs showed a less robust CS-associated regulation 
than human VSMCs under parallel conditions. To determine if SPRR3 protein 
levels were regulated by CS, cell homogenates from cyclically strained (72h) and 
non-strained WT-VSMC were analyzed by immunoblot.  SPRR3 expression was 
detected in WT-VSMCs after 72h CS, but not in unstrained, control samples.  
Expression in mouse esophagus was expectedly very high (Figure 3-4b).128  
Using human and mouse primary VSMCs as well as mouse Tag-VSMCs, we 
demonstrated consistent upregulation of SPRR3 transcripts and protein by CS. 
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Figure 3-4 
 
Figure 3-4 
SPRR3 upregulation in murine VSMCs requires collagen.  SPRR3 transcripts 
(a) and protein (b) upregulated by 72 h CS in WT-VSMCs (n>3 independently 
isolated VSMCs; n=4 independent CS experiments).  Similar fold increase in 
SPRR3 transcripts observed in Tag-VSMCs cultured on type I collagen (n=5) (c), 
but not on poly-L-lysine (n=3, d), or pronectin F (n=3, e, RGD substrate).  
*p≤0.05. 
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Figure 3-5 
 
Figure 3-5 
VSMCs from mice expressed SM α-Actin and SM-myosin heavy chain.  
Representative VSMCs from WT C57 Bl/6 mice (a, WT-VSMC), H-2Kb-tsA58 
mouse (b, Tag-VSMC), α1-integrin knockout (c, α1 KO-VSMC), and α2-integrin 
knockout mouse (d, α2 KO-VSMC) all stained positive for α-SMA (left-hand 
panels) and SM-MHC (right-hand panels).  Each independently isolated primary 
VSMC prep was evaluated once.  Tag-VSMCs were periodically confirmed for 
expression.  20x magnification. 
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SPRR3 mechanoregulation is dependent on binding to collagen.  The 
mechanisms by which mechanical signals are recognized by VSMCs and 
translated into molecular responses are not completely understood.135 Intimal 
VSMCs within atheromas are exposed to an environment rich in ECM, 
particularly (type I) collagen.9  Collagen and other ECM components bind cell 
surface integrins, which serve to connect the ECM to the actin cytoskeleton of 
cells.136  Moreover, changes in traction force initiate intracellular signal 
transduction cascades via “outside in” integrin signaling.136  We investigated 
whether regulation of SPRR3 by mechanical forces was modulated by specific 
extracellular matrices.   
To determine the specificity of SPRR3 regulation for type I collagen, we 
exposed VSMCs to CS on various substrates.  Tag-VSMCs were plated onto 
poly-L-lysine (PLL) (which allows non-integrin mediated adhesion) and pronectin 
F (which contains multiple RGD repeat peptides from human fibronectin) and 
subjected to CS conditons.58, 137  Growth and gross morphology of the VSMCs 
were not markedly altered on these substrates. SPRR3 transcript levels were not 
increased in VSMCs after 72h of CS when cultured on either PLL or on pronectin 
F (Figure 3-4d-e).  In fact, the PLL substrate resulted in a significant relative 
decrease (>2-fold) in SPRR3 transcript level with 72h of CS.  These data 
indicated that SPRR3 regulation required VSMC contact with (type I) collagen. 
 
Integrin α1β1 is necessary for mechanosensitive upregulation of SPRR3.  Based 
on the above data, we chose to investigate the role of the major collagen binding 
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integrins, α1β1 and α2β126, in SPRR3 regulation using function blocking 
antibodies to each of the integrin α1 or α2 subunits.  Tag-VSMCs were 
preincubated with function blocking monoclonal antibodies against α1 or α2 
integrin subunits prior to plating on type I collagen and application of 72h of CS.  
Incubation with α1 integrin subunit blocking antibodies abrogated the CS-
mediated increase in SPRR3 expression (Figure 3-6a).  By contrast, 
preincubation of VSMCs with α2 integrin subunit blocking antibodies induced a 
modest (1.5+.4-fold), but statistically insignificant upregulation of SPRR3 
transcripts.  There was a statistically significant difference in fold-change of 
SPRR3 transcripts between cells exposed to antibodies against α1 versus α2 
(Figure 3-6a).  To further strengthen these findings we utilized genetic models of 
integrin α1 or α2 subunit deletion.  Primary VSMCs were isolated from aortas of 
mice lacking integrin α1β1120 or α2β1.121  VSMC cells derived from both integrin 
α1β1 and α2β1 knockout mice were confirmed to express α-SMA and SM-MHC 
(Figure 3-5).  KO-VSMC primary cells were plated on type I collagen, subjected 
to 72h CS, and assessed for changes in SPRR3 levels as compared to control 
cells without strain.  As expected, the VSMCs from mice lacking integrin α1β1 
failed to upreguate SPRR3 whereas those from integrin α2β1-/- animals showed 
a 2.3+0.6-fold  (p<0.05) increase in SPRR3 transcript and a corresponding 
increase in protein similar to WT-VSMCs (Figure 3-6b,c).   These data help 
explain why SPRR3 expression is limited to atherosclerotic regions of the 
vasculature; SPRR3 regulation will not occur in the absence of integrin α1β1.  It is 
of note that WT-VSMCs and Tag-VSMCs demonstrated enhanced SPRR3 
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Figure 3-6 
 
Figure 3-6 
Transcriptional regulation by CS requires integrin α1, but not α2.  (a) 
Relative fold change in SPRR3 mRNA transcripts in Tag-VSMCs exposed to CS 
following pretreatment with function blocking antibodies (n=4). (b) SPRR3 
transcript levels were measured in primary VSMCs from WT or mice lacking 
designated integrin subunits after 72h CS (n=4 CS experiments from single 
isolation of VSMCs).  (c) SPRR3 protein levels were increased in primary VSMCs 
from integrin α2β1-/- mice following 72h CS, but not in integrin α2β1-/- mice, as 
determined by immunoblot.  *p≤0.05, NS: not significant. 
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regulation when the cells had been cultured for 48h prior to stress in 200pM 
TGF-β (Figure 3-7b).  This observation was likely due to the upregulation of the 
integrin α1 subunit when VSMCs were cultured in 200pM TGF-β (Figure 3-7c); 
Furthermore, it is known that VSMCs in prolonged culture downregulate integrin 
α1β144.  Consistent with this, we did not observe SPRR3 regulation with cyclic 
strain using cells in prolonged culture (over 9 passages) (Figure 3-7a). It should 
be noted, however, that there are numerous other cytokines and signaling factors 
which are known to affect integrin expression and these, as well as or in addition 
to TGFβ, may be influencing α1β1 integrin expression in atheromas.138   
To confirm the relevance of integrin α1β1 in this system, we assessed 
whether α1β1 integrins were expressed in VSMCs of atheromas.  Proximal 
aortas from ApoE-/- mice containing atherosclerotic lesions were co-stained with 
antibodies against α1 or α2 integrin subunits and anti-SM α-actin antibodies.  
Expression of integrin α1 subunit was co-localized with the VSMC marker (Figure 
3-8a-d), whereas no discernible integrin α2 staining was observed in this mouse 
atherosclerosis model. 
 
Discussion 
This study was designed to investigate the physiologic basis for atheroma-
enriched expression of the SPRR3 protein demonstrated in both human and 
murine vasculature.  Our results indicated that prolonged (>48 hr) CS of 20% 
resting length produced upregulation of SPRR3 RNA and protein in VSMCs.  By 
contrast, exposure of VSMCs to varying amounts of shear stress or lipids failed 
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Figure 3-7 
 
Figure 3-7 
Altered SPRR3 regulation. (a)  WT-VSMCs maintained over passage 9 did not 
regulate SPRR3 transcripts following 72h CS.  (b)  WT-VSMCs exposed to CS in 
the presence of 200pM TGF-β showed enhanced expression of SPRR3 relative 
to those maintained in media lacking TGF-β.  (c)  Surface expression of the α1 
integrin subunit detected by flow cytometry was increased on Tag-VSMCs when 
cultured in 200pM TGF-β.  n=4 *p≤0.05 statistically significant; NS:  Not 
significant. 
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Figure 3-8 
Figure 3-8 
Integrin α1, but not α2, is expressed in VSMCs in atheromas.  Indirect 
immunofluorescence of representative proximal aorta lesion from ApoE-/- mice 
(H&E, a,e) showed co-expression of α-SMA (b, f, green) and integrin α1 (c, red). 
(d) Merge, co-localization (yellow) marked by arrowheads.  Integrin α2 
expression was not detected, (g) Scale bar = 20µm, 40x magnification.  L 
indicates vessel lumen. 
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to increase SPRR3 transcript levels (Figure 3-3).  To our knowledge this is the 
first atheroma-specific protein whose expression is biomechanically regulated.  It 
is of some interest that SPRR3 co-distributed with SM-myosin heavy chain in 
hVSMCs (Figure 3-3b).  SM-MHC has previously been shown to be both 
biomechanically regulated as well as biomechanically active and hence this 
finding supports a role for SPRR3 in biomechanics.129, 130  Because integrins are 
hypothesized to serve as prime cellular mechano-sensors, as they link the 
interior and exterior of the cell116, 139, we sought to elucidate the effect of ECM 
and integrins in mechanoregulation of SPRR3 transcription.  By exposing VSMCs 
to CS on various substrates, we demonstrated that SPRR3 regulation by CS 
required type I collagen, whereas cells grown on PLL or pronectin F failed to 
regulate SPRR3 with CS.  Since type I collagen constitutes >70% of all collagen 
in atheromatous plaques, it represents the primary ECM circumscribing VSMCs 
within lesions.131  Given that the CS effect required a collagenous substrate, we 
evaluated the role of the major collagen binding receptors, α1β1 and α2β1, in 
SPRR3 gene regulation using both an immunoblocking approach and a genetic 
deletion model.  Taken together, the data suggest that the α1β1 collagen-binding 
integrin is required for mechanoregulation of SPRR3. Consistent with published 
studies, we confirmed integrin α1 subunit expression in VSMCs within murine 
lesions140.  Expression of the integrin α2 subunit was not evident in murine 
lesions as is consistent with previous findings.44, 141 
Since VSMCs are exposed to mechanical forces such as CS in healthy 
arteries as well as in atheromas, our findings do not fully explain why SPRR3 
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expression was restricted to plaques.  One possibility for this phenomenon 
relates to the microenvironment of the plaque itself.  VSMCs as well as 
macrophage foam cells are known to take up lipid in atheromas, so we 
investigated if lipid loading could upregulated SPRR3 transcript.142  LDL and ox-
LDL failed to enhance SPRR3 expression, although ox-LDL loading resulted in 
decreased SPRR3 transcription.  While it is unclear why this may have occurred, 
it is known that lipid-loading VSMCs induces a variety of signaling pathways, as 
well as inducing an even more synthetic cellular phenotype.143-145  Therefore, 
cells with an altered phenotype, in the absence of biomechanical stress, may 
downregulate SPRR3.  However, this raises the issue of VSMC phenotype (e.g., 
contractile/differentiated vs. synthetic) as a variable in this system.  VSMCs in the 
context of the atherosclerotic plaque are widely considered to reside in the 
synthetic state.145, 146  Because this study investigates the regulation of SPRR3 in 
the context of the atherosclerotic plaque, it is optimal to use cells in vitro under 
culture conditions which promote a synthetic phenotype.  SM-MHC is a marker of 
a differentiated/contractile VSMC.  As seen in Figure 3-3 and 3-5, the VSMCs 
used in this study express low levels of this protein, suggesting that they are in a 
relatively synthetic state.    Another potential explanation may be that VSMCs 
within atheromas upregulate α1β1 expression.  We have observed in vitro 
downregulation of the integrin α1 subunit in some VSMCs after prolonged 
culture; these cells fail to demonstrate SPRR3 regulation (Figure 3-7a).44  It is 
known that lesions locally express high levels of TGFβ, which is known to 
upregulate collagen and surface integrin expression32, 147, 148.  We confirmed this 
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finding by demonstrating that TGFβ increased expression of α1β1 in cultured 
VSMCs.  Accordingly, VSMCs upregulated SPRR3 in response to CS more 
robustly when cultured in the presence of 200pM TGFβ (Figure 3-7b,c).  We also 
demonstrated highly localized expression of α1β1 on VSMCs constituting murine 
proximal aorta lesions.  Hence, one hypothesis is that the atheroma 
microenvironment (inflammation, altered local compliance, etc.), perhaps through 
increased TGFβ, altered VSMC integrin expression and subsequent 
ECM/integrin signaling. However, other cytokines also present in this 
microenvironment may also be responsible for the integrin regulation.138   
Moreover, to further examine if biomechanical stress alone could upregulate 
SPRR3, we examined aortas isolated from mice subjected to continuous infusion 
of angiotensin II (Ang II) for two months, which induces systemic hypertension 
associated with increased medial thickness as compared to saline controls 
(samples obtained from Dr. Nancy J. Brown, Vanderbilt University).149   We failed 
to detect either α1β1 or SPRR3 expression in arterial wall VSMCs in treated or 
control aortas (Figure 3-9).    Together, the data suggest that biomechanical 
stimulation alone in vivo or in vitro was not sufficient for upregulation of SPRR3 
transcript and protein expression in the absence of VSMC α1β1 integrin 
expression.  A model of this proposed mechanism is shown in Figure 3-10.  
Nevertheless, the atherosclerotic plaque is a complex tissue with multiple 
variables that may affect the transcription of SPRR3.  While many excellent 
studies have highlighted integrin/matrix interactions in regulating the physiology 
and gene expression in VSMCs, to our knowledge our study is among the first to 
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Figure 3-9 
Figure 3-9 
SPRR3 regulation in hypertension.  (a)  The effect of AngII-infusion on mouse 
aortic morphology.  Note the increased medial thickness in the AngII-treated 
animals (n=6, vehicle control, n=7, AngII infused).  (b)  Aortas from AngII-infused 
and vehicle-control animals were subjected to immunostaining for SPRR3, but 
were all negative for SPRR3 expression.  (c)  Serial sections to those used to 
immunostain for SPRR3 were subjected to indirect immunofluorescent analysis 
for α-SMA (green) and anti-integrin α1 subunit (red).  No α1 expression was 
detected on VSMCs. 
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Figure 3-10 
 
Figure 3-10 
Model of SPRR3 regulation in VSMCs. 
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delineate a direct relationship between transcription of a mechanosensitive target 
gene and specific integrin/ECM signaling. 
The function of SPRR3 in VSMCs within atheromas remains unclear.  The 
architecture of SPRR3, which is transglutaminated via its N- and C-terminal 
domains to other structural proteins, including other SPRRs, is believed to play a 
central role in the barrier and stress function of the cornified envelope.80  The 
central core of SPRR3 is considered to have virtually no secondary structure, a 
vital characteristic in its function as a flexible cross-bridge between its binding 
partners.150, 151 SPRR3 is a substrate for transglutaminase (TGase) types I and 
III, which are expressed in murine vessels.64, 150, 151   Interestingly, other studies 
have linked increased TGase activity to VSMCs and sites of atherosclerosis152, 
153, although no reports are available on the relationship between SPRR3 (or any 
substrates) and TGase gene family in VSMCs.  It is tempting to speculate that 
SPRR3 may serve as a crosslinking substrate for TGase to stabilize the 
cytoarchitecture of VSMCs, although the relationship between SPRR3 and 
transglutaminases in the vasculature remains unexamined.  Our data showing 
that SPRR3 is exclusively enriched in VSMCs within atheromas in response to 
mechanical stress implies that it may play a role in altered biomechanical 
compliance of the smooth muscle cell within an atheromatous lesion.  Efforts in 
our lab are currently underway to better understand the role of SPRR3 within 
VSMCs using gene deletion models and identifying its crosslinked partners.   
It has been reported that early atherosclerotic lesions (undetectable by 
angiography but evident by intravascular ultrasound and postmortem 
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histopathology) result in significantly reduced aortic compliance in a 
hyperlipidemic rabbit model.106  These data have been confirmed by other 
studies by multiple groups.154-156  One mechanism by which even an early 
atheroma may alter local biomechanics is from the direct effect of cholesterol on 
VSMC membrane fluidity.  Alternatively, alterations of the physical properties of 
the ECM can be transduced to VSMCs.24, 157, 158  While much data support that 
atherosclerosis itself alters vessel compliance and, thereby, biomechanical 
properties, the molecular changes within VSMCs in response to altered local 
biomechanics are poorly understood.  This paper elucidates the mechanism by 
which SPRR3 is regulated by mechanotransduction in VSMCs within the context 
of the microenvironment of the atherosclerotic plaque.   
While a mechanism for SPRR3 regulation has been established, the 
function of the protein in VSMCs remains to be determined.  The following 
chapter will show data to test the hypothesis that SPRR3 functions by binding 
through transglutamination to other proteins. 
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CHAPTER IV 
 
FUNCTION OF SPRR3 IN VSMCS 
 
Introduction 
 VSMCs within the context of the atherosclerotic microenvironment are 
distinct from the smooth muscle cells in the adjacent normal tissue, as there are 
a distinct set of responses of VSMCs as they adapt to the atherosclerotic 
milieu.159  For example, VSMCs within an atheroma are more proliferative, 
migratory, and synthetic.46  Furthermore, as discussed in Chapter I, one 
distinction between normal and atherosclerotic tissue is decreased vascular 
compliance in the atheroma.  Work in the field of biomechanics has shown that 
as extracellular forces increase, either directly (pushing or pulling on the cell 
itself) or indirectly (tension from stiffening matrix/decreased compliance), 
numerous changes arise within the cell.  Stiffening in the ECM and generation of 
mechanical force leads to construction of new adhesion complexes and 
cytoskeletal rearrangement.  Together, these responses to force result in a stiffer 
cellular architecture.160, 161  Cellular stiffening is further increased by 
rearrangement and activation of cytoskeletal crosslinking proteins.160-163  These 
and other responses may help the cell adapt to the compliance changes in the 
surrounding microenvironment.  
We propose that SPRR3 acts in the atherosclerotic VSMC as an adaptive 
response to the altered compliance.  Specifically, we hypothesize that within 
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high-compliance atherosclerotic tissue SPRR3 is bound by transglutamination at 
its N- and C- termini to the high tension cytoskeletal elements, where it acts as a 
crosslinker and serves to dissipate stress applied to the cell (see Figure 4-1).  
This model is consistent with previous work on SPRR3 which implicated it as a 
flexible crosslinker of structural cornified envelope proteins.75, 80  Previous studies 
of SPRR3 localized the protein to the cellular perimeter in the cornified envelope 
of stratified epithelial cells.  However, in VSMCs SPRR3 is localized within a 
cytoplasmic network when the cells are exposed to cyclic strain.164  This 
distribution suggests that SPRR3 functions in a unique role in the vasculature, 
specifically in vascular adaptation to altered vessel compliance in 
atherosclerosis.   
 
Methods 
Cell culture:   
VSMCs were isolated from the aortas of H-2Kb-tsA58119 transgenic mice 
(Tag-VSMCs).  The vessels were cleaned of adventitia, cut longitudinally, and 
the lumen was scraped to remove the endothelium.  Segments from the media 
were cut into 1mm2 pieces and cultured in 15% 
FBS/DMEM/Penicillin/Streptomycin until outgrowth of cells.  VSMCs were 
assessed by immunofluorescence with anti-smooth muscle α-actin (α-SMA, 
1:1000), anti-SM myosin heavy chain (SM-MHC, 1:250), and anti-vWF (1:200).  
Experiments were only performed with cultures that were 95%-100% α−SMA and 
SM-MHC positive and vWF negative.  Tag-VSMCs were culture expanded at 
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Figure 4-1 
 
 
 
Figure 4-1 
Hypothesized function of SPRR3.  Under normal conditions, large arteries 
remain soft and highly compliant with low ECM content and the cytoskeleton of 
VSMCs within the arterial wall is under relatively low tension.  Thus, the artery 
can distend and retract during systole and diastole, respectively.  However due to 
ECM remodeling, calcification, and increased cellular content within the 
atherosclerotic milieu, the vessel wall becomes decreasingly compliant.  As the 
microenvironment stiffens, cytoskeletal tension builds within the intimal VSMCs.  
We hypothesize that SPRR3 is covalently bound through transglutamination to 
cytoskeletal elements and yields flexibility to the otherwise stiff cytoskeleton. 
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33oC in the presence of 10ng/mL interferon-γ (this permits transformed-like 
phenotype) and subcultivated for 10 days (5 passages) in regular media at 37oC 
(this reverts the cells to a primary-like phenotype) prior to use.124   
 For retroviral transduction, wild type (WT) or mutant SPRR3 cDNA was 
subcloned into the LZRS-MS-IRES-GFP retroviral expression vector (a kind gift 
of Alyssa Weaver, Vanderbilt University) and transfected into Phoenix 293 
packaging cells (maintained in 10% heat-inactivated FBS in DMEM).  Phoenix 
cell transfection, viral harvest, and target cell transduction were performed as 
previously described.165  Forty-eight hours following transduction, the transduced 
Tag-VSMCs were assessed for GFP expression and sorted by flow cytometry to 
enrich for GFP-positive cells.  Transduced Tag-VSMCs will be referred for the 
remainder of the text as follows: 
Tag-VSMC+GFP (GFP-only, empty vector control) 
Tag-VSMC+WT (wtSPRR3-IRES-GFP construct) 
Tag-VSMC+ ΔX (mutant SPRR3-IRES-GFP construct) 
Mutational cloning:   
Specific deletions of the wild-type SPRR3 cDNA were generated using 
QuikChange Mutagenesis as described elsewhere.166  The mutant constructs are 
detailed in Figure 4-2. 
Migration Assay: 
 Tag-VSMC migration was assessed using a modified Boyden-chamber 
assay as previously described.167  Briefly, 70% confluent Tag-VSMCs with 
various transducts were subjected to serum-starvation overnight in 1% 
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Figure 4-2 
 
 
Figure 4-2 
Graphic illustration of various SPRR3 WT and mutant constructs.  TGase 
substrate domains are highlighted in red in the amino acid sequence (a) and in 
the graphic depictions of the protein (b).    
a 
b 
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FBS/DMEM.  Cells were harvested, and 4x103 cells were added to the upper 
chamber of the apparatus with 15% FBS/DMEM in the lower chamber, and 
incubated for 5hr.  Filters were fixed for 20min in 4% paraformaldehyde and 
stained with crystal violet.  The number of cells migrated to the lower chamber 
were counted in each of eight high power fields per filter.  Migration was 
assessed in triplicate for each cell type.   
Proliferation Assay: 
 Tag-VSMC with various transducts were assessed for BrdU incorporation 
as well as Ki-67-staining nuclei to determine proliferative indexes.  For BrdU 
incorporation, cells were plated at 500 and 1,000 cells/well of a 96-well plate and 
grown in 15%FBS/DMEM.  For Ki67 staining, cells were plated at 10% 
confluence on glass coverslips coated with PBS, fibronectin (20μg/mL), collagen 
I (0.1mg/mL), gelatin (0.2%).  When the cells reached approximately 90% 
confluence, the coverslips were fixed and stained as described elsewhere.168 
Collagen Gel Contraction:  
Tag-VSMCs at 60% confluence were harvested with trypsin and 2.5x105 
cells/mL (final concentration) were dispersed into collagen gels (1.25mg/mL final 
collagen concentration) and 0.3mL were plated in each well of a 24-well plate.  
After the gels solidified at 37oC for 30min, they were manually detached from the 
sides of the wells with a 30-gauge needle and 1mL media was added to maintain 
the cultures.  The plates were scanned at defined time points and the area of the 
gels in pixels was calculated with MetaMorph Imaging system (Molecular 
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Devices, Sunnyvale, CA).  Contraction was assessed in triplicate for each cell 
type. 
Immunoblot and Immunoprecipitation:  
Tag-VSMCs were grown to 90% confluence and harvested by scrapping 
in RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 
0.05% SDS, protease inhibitors).  Protein concentration was determined by a 
BCA protein assay (Thermo Fisher).  For immunoprecipitation, cell lysates were 
pre-cleared against protein A beads and immunoprecipitated with protein A 
beads cross-linked (in 0.2M TEA pH 8.2) to a SPRR3 antibody.  Samples were 
separated on SDS-PAGE gels.  Immunoblotting was carried out as described 
elsewhere.36  Primary antibodies used were anti-hSPRR3 (clone 4a, 1:1000), 
anti-smooth muscle α-actin (1:5000) and anti-β-actin (1:5000) with appropriate 
HRP-conjugated secondary antibodies.   
 
Results 
Generation of Tag-VSMC lines overexpression wtSPRR3 and deletion mutants.   
To better understand the function of SPRR3, we generated VSMCs which 
constitutively expressed the human SPRR3 gene using a retroviral transduction 
system in the mouse-derived Tag-VSMCs.  This allowed very specific detection 
of the overexpressed SPRR3 using an antibody which expressly recognized 
human SPRR3.  There is no endogenous mouse SPRR3 detected in the Tag-
VSMCs (consistent with findings in the previous chapter that SPRR3 expression 
was stress-dependent, see Figure 3-4b), but the human protein was robustly 
expressed following retroviral transduction (Figure 4-3a).  Immunoblot for SPRR3 
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Figure 4-3 
 
 
 
Figure 4-3 
 wtSPRR3 overexpression in Tag-VSMCs.  Human SPRR3 expression was 
driven in Tag-VSMCs, and detected by immunoblot using an antibody specific for 
human SPRR3.  Three bands were observed with SPRR3 overexpression: 
25kDa, 30kDa, and 60kDa (a).  Mutant human SPRR3 constructs with various 
TGase domain deletions were also detected by immunoblot (b).  Molecular 
weight markers given in kilodaltons (kDa). 
a 
b 
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showed three prominent bands, one at approximately 25kDa, which represents 
monomeric SPRR3, one band at 30kDa, and another at 60kDa.  This is 
consistent with the notion that SPRR3 is transglutaminated to itself and/or other 
proteins.63  Transglutamination is a covalent linkage of two proteins through a ε-
(γ-glutamyl)lysine isopeptide bond which is not readily disrupted by reducing 
conditions.150  Furthermore, as SPRR3 has been shown to be transglutaminated 
at amino acids Q5-Q8, Q17-Q22, and K159-K161, we generated deletion 
mutants of each of these putative transglutaminase (TGase) domains.63  The 
same pattern of bands was observed for the WT and mutant constructs.  The two 
higher molecular weight bands were believed to be protein complexes containing 
SPRR3 covalently bound to an unknown protein through the action of TGases.  
However, as these bands remain in all the mutant constructs, it is unlikely that 
the bands arise from transglutamination.  Alternately, other TGase domain sites 
may exist on SPRR3 which were not identified by in vitro TGase assays.63  In 
order to determine the identity of the higher molecular weight bands detected by 
immunoblot, we performed immunoprecipiations (IP) with the same antibody 
used for immunoblot.  Multiple attempts were made to IP a sample which could 
be identified by proteomic analysis.  However, none were successful and the 
nature of the higher molecular weight bands remains unknown (representative 
experiment shown in Figure 4-4).   
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Figure 4-4 
 
Figure 4-4 
IP of SPRR3 brought down neither SPRR3 nor any binding partners.  This 
image is from a single representative experiment.   A small amount of input 
lysate was run in lane 1 for comparison (* monomeric SPRR3 in control lane).  
No unique bands were detected from the IP of lysates from cells overexpressing 
SPRR3 compared to PBS-only input control or lysate from GFP-only expressing 
cells.  Molecular weight markers given in kDa. 
 
1 2 3 4 
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 Overexpression of wtSPRR3 affected proliferation, migration, and contraction.   
Since the proliferative activity of VSMCs is altered in atherosclerosis, we 
sought to determine the rate of proliferation of the Tag-VSMC+GFP and Tag-
VSMC+WT cells using two assays.  A BrdU-incorporation assay in which the 
cells were plated directly onto the plastic tissue culture dish overnight followed by 
a 24h pulse of BrdU.  This revealed decreased proliferation of the Tag-
VSMC+WT (Figure 4-5a).  Furthermore the same cells were plated at a very low 
concentration (around 10% confluence) on glass coverslips coated with various 
ECM components for 5-7 days and growth was assessed by Ki67-positive nuclei.  
In this case the Tag-VSMC+WT cells proliferated significantly faster than control 
when plated on PBS-coated coverslips.  However, those cells grown on 
coverslips coated with fibronectin, gelatin, or collagen showed equal proliferation 
between Tag-VSMC+wtSPRR3 and control cells (Figure 4-5b).  There are 
several possible causes for the inconsistency between the different proliferation 
assays.  Firstly, the substrates are different in all cases: tissue culture plastic, 
glass, or ECM-coated glass.  The interaction of each of these substrates with the 
cells is undoubtedly different and therefore may be responsible for the different 
proliferative indexes.60  Secondly, the cells were grown at different densities in 
the two assays.  Cell were grown very sparsely on coverslips for a prolonged 
period of time, whereas in the BrdU-incorporation assay the cells were at a 
relatively high density for a short time.  The molecular events underlying these 
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Figure 4-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5 
SPRR3 overexpression alters Tag-VSMC proliferation.  BrdU-retention after 
24hr reveals a decrease in proliferation when cells overexpress SPRR3 (a).  
However, when plated at a low concentration and grown for several days on 
coated glass coverslips, the opposite effect is observed, that overexpression of 
SPRR3 promotes proliferation (b). *p≤0.05 
a 
b 
*
* 
Tag-VSMC +GFP 
Tag-VSMC +WT 
Tag-VSMC +GFP 
Tag-VSMC +WT 
Collagen 
Type I 
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divergent results could provide some insight as to the function of SPRR3 in the 
future. 
 Since VSMC migration is a key step in atherosclerotic plaque progression, 
the cells were also assessed for their ability to migrate.  As shown in Figure 4-6a, 
Tag-VSMC+WT migrated about 1.7+/-0.003-fold (p=1.4x105) more efficiently 
than control cells.  The fact that SPRR3 expression promotes migration suggests 
that SPRR3 may play a role in the important step of VSMC migration from the 
media to intima in atherosclerosis progression. 
 Another characteristic of VSMCs within an atherosclerotic plaque is 
decreased contraction as the cells de-differentiate into a synthetic phenotype.  
Therefore, we determined the contractile capacity of the cells expressing SPRR3 
using a collagen gel contraction assay.  This revealed that Tag-VSMC+WT 
demonstrated a diminished ability to contract a collagen gel over time (Figure 4-
6b, p≤0.002).  These data showing increased migration and decreased 
contraction with SPRR3 expression were consistent with known behavior of 
VSMCs within an atheroma. 
TGase inhibition  
 To test the hypothesis that transglutamination of SPRR3 is required for its 
function in VSMCs, we employed the TGase inhibitors, methyldansylcadaverine 
(MDC) and cystamine.  These compounds function by competitive inhibition and 
active-site blocking of TGases, respectively.169  Surprisingly, the higher molecular 
weight bands observed by immunoblot were not abrogated by 24h treatment with 
either TGase inhibitor (Figure 4-7).  These findings suggest that SPRR3 existed 
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Figure 4-6 
Figure 4-6 
SPRR3 overexpression decreases Tag-VSMC contraction of collagen gels.  
Overexpression of SPRR3 in Tag-VSMCs produces a 1.73-fold increase in 
migration compared to GFP-only controls (a).  The Tag-VSMC+WT cells, 
however, are less contractile than control cells, as evidenced by a relative 
inability to contract a collagen gel (b). *p≤0.002 
 
a 
b 
* 
* * 
Tag-VSMC +GFP 
Tag-VSMC +WT 
Tag-VSMC +GFP 
Tag-VSMC +WT 
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only in a monomeric form and that the higher molecular weight bands are non-
specific artifacts associated with SPRR3 overexpression.  Alternately, because 
TGase-generated covalent bonds are non-reversible, it is possible that the higher 
molecular weight protein complexes were generated prior to TGase inhibition and 
are still observed due to a slow protein turn-over. 
 Although we could not detect changes in the stead-state population of 
SPRR3 with TGase inhibition, we sought to assay these treatments on active 
cellular processes.  To test the effect of TGase inhibition on SPRR3 function, 
Tag-VSMCs+/-SPRR3 were pretreated for 24h with TGase inhibitors and then 
subjected to migration analysis.  As seen in Figure 4-8, use of either TGase 
inhibitor reversed the effect of overexpressing SPRR3 in a dose-dependent 
manner.  These data were seemingly in conflict with the immunoblot which 
suggested that transglutamination does not affect SPRR3.  It is possible that the 
results observed using the TGase inhibitors were due non-specific effects; MDC 
and cystamine are known to produce off-target results on cultured cells.170, 171  
This may also explain the increased migration in control cells with inhibitor 
treatment. 
 
SPRR3 mutants 
 As an alternate approach to TGase inhibition, the SPRR3 TGase-
substrate domain mutants were employed to more specifically determine the 
effect of transglutamination on SPRR3 function.  A number of possible protein-
protein binding interactions can be envisioned based on these three TGase-
substrate domains.  As shown in Figure 4-10, SPRR3 could be bound to other 
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Figure 4-7 
 
 
 
Figure 4-7 
TGase inhibition does not affect the banding pattern of SPRR3 as detected 
by immunoblot.  Tag-VSMCs +/- SPRR3 were grown in the presence of TGase 
inhibitors, MDC (a) or cystamine (b) for 24h.  Molecular weight markers given in 
kDa. 
 
a b 
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Figure 4-8 
 
Figure 4-8 
TGase inhibition decreases Tag-VSMC+WT migration.  Pretreatment with 
either TGase inhibitor (cystamine (a) or MDC (b) decreases Tag-VSMC+WT 
migration while Tag-VSMC+GFP migration increases, both in a concentration-
dependent manner. 
 
a 
b 
Tag-VSMC +GFP 
Tag-VSMC +WT 
Tag-VSMC +GFP 
Tag-VSMC +WT 
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SPRR3 molecules through any of those domains, as well as to other proteins, 
thereby producing the multiple bands observed by immunoblot for SPRR3.  
However, consistent with the TGase inhibition immunoblot, when these mutant 
constructs were expressed in Tag-VSMCs, the same banding pattern as 
wtSPRR3 was observed (Figure 4-3b).  If any of the deleted domains are 
normally covalently bound to any other protein, the banding patterns should shift 
in either size or intensity with some of the mutant constructs.  Therefore, these 
data suggested again that transglutamination of SPRR3 does not occur in this 
system with VSMCs. 
 Migratory and contractile capabilities of the cells with mutant SPRR3 
constructs were assessed in comparison to GFP and wtSPRR3 transduced cells.  
As shown in Figure 4-9, only cells containing constructs with the Δ1 mutation (Δ1, 
Δ1/2, Δ1/2/3) demonstrated behavior similar to control cells, whereas the other 
mutants were phenotypically similar to those expressing wtSPRR3.  Cells 
carrying a construct with a single deletion at site 1 alone also contracted and 
migrated like control cells (data not shown).  Furthermore, in the contraction 
assay, cells containing mutants Δ2 and Δ3 are unable to contract the collagen 
gel.  The divergent results between the migration and contraction assays 
(migration suggests that Δ2 and Δ3 are non-functional, while the contraction 
assay shows an effect of these regions opposite of the Δ1 region) indicate a 
possible role for the amino acids in regions 2 and 3 in contraction only, but not in 
migration.  However, the role of SPRR3 in both migration and contraction is 
ablated in the Δ1 mutant, indicates a requirement for amino acids 5-8 in SPRR3 
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Figure 4-9 
 
 
Figure 4-9 
SPRR3 mutant constructs affect VSMC migration and contraction.  Tag-
VSMCs overexpressing mutant SPRR3 constructs with site 1 deleted (Δ1, Δ1/2, 
and Δ1/2/3) migrate (a,c) and contract (b) at levels similar to Tag-VSMC+GFP.   
c 
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Figure 4-10 
 
 
Figure 4-10 
Possible arrangements of SPRR3 binding to other SPRR3 molecules 
(homodimer) or other proteins.  Theoretically, SPRR3 could be bound to other 
SPRR3 molecules and other proteins through binding at the three TGase 
domains, site 1 (red), 2 (yellow), and 3 (blue).  SPRR3 molecules could pair with 
each other through any combination of these domains, as shown (a-f) or with 
another TGase domain-containing protein (g). 
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(those deleted in the Δ1 mutant).  If the phenotype were the result of 
transglutamination of two SPRR3 molecules binding to each other through site 1, 
then two molecules of SPRR3 would bind to each other as shown in Figure 4-
10c, and would result in a 50kDa SPRR3 homodimer.  However, this cannot be 
the case, as the 50kDa band observed by immunoblot remains in the Δ1 mutant 
cells (Figure 4-3b).  Therefore, the effect mediated through amino acids 5-8 of 
SPRR3 are not likely the result of transglutamination.  Unfortunately, this 
experiment did not definitively prove that SPRR3 was not transglutaminated.  A 
more compelling experiment to demonstrate the transglutamination state of 
SPRR3 would be to utilize proteomic analysis of the various SPRR3 constructs 
isolated from Tag-VSMCs.  We have made multiple attempts to do so, but have 
been unable to successfully purify and analyze SPRR3 from that system.  
Furthermore, preliminary data discussed in the next chapter, as well as recent 
work from another group suggests that SPRRs may function independently of 
transglutamination.172  Therefore, we feel that the hypothesis that SPRR3 
functions in VSMCs via transglutamination was incorrect. 
 
 
Discussion 
 The hypothesis driving the work shown in this chapter was that SPRR3 
functions as a flexible crosslinker in the cytoskeleton of VSMCs via 
transglutamination.  However, the data present above indicated that the function 
of SPRR3 is independent of transglutamination of the protein.  When wtSPRR3 is 
expressed in Tag-VSMCs, immunoblot analysis for SPRR3 revealed three 
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distinct, specific bands: one at approximately 25kDa (the predicted size of 
SPRR3) and two of higher molecular weights, suggesting that SPRR3 was 
covalently bound to some other molecule, presumably through 
transglutamination.  Moreover, wtSPRR3 expression also lead to decreased 
proliferation and contraction and increased migration.  Treatment of the SPRR3 
overexpressing cells with TGase inhibitors yielded a dose-dependent decrease in 
Tag-VSMC+WT migration.  However, the control cells also underwent a dose-
dependent increase in migration and the banding pattern by immunoblot 
remained unchanged with TGase inhibitor treatment.  These data produced an 
unclear picture of the role of transglutamination in the function of SPRR3.  To 
more directly address the issue of SPRR3 transglutamination, specific deletion 
mutants of the TGase-substrate domains of SPRR3 were overexpressed in Tag-
VSMCs.  Migration and contraction of cells containing SPRR3 with the Δ1 site 
missing reverted to control levels, thereby indicating a dependence on the 
residues within the Δ1 site for SPRR3 function.  However, this does not appear to 
be a TGase-dependent function, as the higher molecular weight moieties 
observed by immunoblot were not affected in the Δ1 mutant constructs.  The 
function of SPRR3 in VSMCs remains uncertain, though it is evident that the 
region containing amino acids 5-8 is required for its function.  Further mutational 
analysis will be required to determine which of these residues, either alone or in 
combination.   
 While these three assays mimic effects observed in VSMCs of atheromas, 
it should be noted that these are not all believed to act through the same 
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pathways.  VSMC migration, contraction, and proliferation have all been shown 
to be affected by fibroblast growth factor, AngII, NADPH oxidase, PPARα, PKC, 
Ras, cAMP, PI3K, Akt, NF-κB, MAP-kinases, p38, JNK, and p16.173-177  Given 
this broad array of pathways, we were surprised to see SPRR3 having an effect 
on proliferation, migration, and contraction.  It is unlikely that SPRR3 is acting at 
a common point and affecting VSMCs in the same manner for each assay.  This 
is supported by the fact that mutants Δ2 and Δ3 behave like WT SPRR3 in the 
migration assay, whereas cells expressing these constructs are completely 
unable to contract a collagen gel, unlike WT SPRR3.  This suggests that different 
regions of SPRR3 may be required for different VSMC functions.  Future work 
will continue to pursue the effects of amino acids 5-8 in SPRR3 function. 
Recent work has implicated a non-structural role for another SPRR family 
member, SPRR2a, in biliary epithelial cells.172  Based on this work and emerging 
preliminary data from our laboratory, it seems likely that SPRR3 may function in 
VSMCs to modulate intracellular signaling cascades, although the precise 
mechanism is yet to be elucidated.  Nevertheless, it is clear that SPRR3 
expression affects VSMC proliferation, migration, and contraction.  Each of these 
processes likely plays a role in how cells within an atheroma adapt and react to 
the altered local microenvironment. 
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CHAPTER V 
 
DISCUSSION AND FUTURE WORK 
 
 The studies presented in this document demonstrate our work on the 
regulation and function of SPRR3.  We have shown that SPRR3 expression is 
regulated in VSMCs of atheromas by cyclic strain as the cells sense the 
microenvironment via α1β1 integrin.  We hypothesized that SPRR3 functions 
within VSMCs by transglutamination to structural proteins.  However, the work 
presented in chapter IV lead us to conclude that SPRR3 likely functions through 
a different mechanism.  Future work on SPRR3 will investigate an alternative 
function for SPRR3.  Our lab has also generated a mouse deficient in SPRR3 
which will be studied in order to gain more insight into SPRR3 function.  These 
studies, particularly those in chapters II and III, serve as a reminder of the 
importance of the cellular microenvironment, a concept which has broad 
applications to cell biology.  Finally, the novel discovery of SPRR3 as a specific 
marker of atherosclerosis makes it a prime candidate for development as a 
biomarker of atherosclerosis.   
 
SPRR3 in intracellular signaling 
A recent paper has suggested a function for an SPRR family member, 
SPRR2A, as a non-structural, signaling-related protein.172  SPRR2A 
overexpression in biliary epithelial cells (BECs) decreases proliferation, increases 
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migration, and promotes a degree of epithelial to mesenchymal transition (EMT).  
Furthermore, SPRR2A was shown to be protective in response to BEC oxidative 
injury, which is consistent with another publication in which SPRR1a was shown 
to be cardioprotective following ischemic injury.105, 172  Moreover, rather than 
acting in a structural manner, SPRR2A contains multiple sequences within its 
proline-rich region which act as SH3 ligand domains, and interacts with several 
SH3-containing proteins in vitro, including Src, Yes, and Abl.  The authors 
suggest that the sequence PXPPXP (where P is proline and X is usually an 
aliphatic residue) is required for this function.172  While many PXPPXP regions 
exist in SPRR3, they reside in the central domain and were therefore not directly 
affected by any of our mutant constructs.  However, other putative functional 
domains in SPRR3 have been predicted by computational analysis.178  
Specifically, there is a class IV WW ligand domain (similar in function to SH3 
ligand domain) at aa8-13, a region which is disrupted in the Δ1SPRR3 mutant.179  
The WW domain functions in a range of protein-protein interactions, particularly 
in linking signaling between the membrane and the cytoskeleton.179  Currently, 
known WW domain-containing proteins include Pin 1, Nedd4, and WW-2.179  
While there is no known connection between SPRR3 and any of these proteins, 
the role of the WW-ligand interaction in relating signals from the cell membrane 
to the cytoskeleton suggests a possible function for SPRR3 as a signaling 
molecule.  Future studies will address the biological role of the WW ligand 
domain using mutagenesis to determine which amino acids in the Δ1 region are 
required for SPRR3 function. 
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We hypothesize that SPRR3 regulates Akt phosphorylation, thereby 
promoting cell survival. This is supported by the fact that overexpression of 
wtSPRR3 results in an increase in Akt phosphorylation, an effect which is 
abrogated in the Δ1SPRR3 mutant (Figure 5-1).  This was through PI3K activity, 
as evidenced by the lack of phosphorylation of Akt following incubation with the 
PI3K inhibitor, LY294002.   Akt phosphorylation by phosphatidylinositol 3-kinase 
(PI3K) is primarily associated with promoting cell survival by evading apoptosis 
and it is possible that SPRR3 overexpression may lead to enhanced cell 
survival.180  Cells overexpressing either SPRR1A or SPRR2A have better 
survival, though not necessarily in an Akt-dependent manner.105, 172  
Furthermore, SPRR2a and 2b is upregulated in bronchial epithelium following an 
allergic challenge and inflammation and SPRR1a has been shown to be 
expressed as an adaptive response to ischemic stress in cardiomyocytes as well 
as in neurons following peripheral axonal damage,.105, 181, 182  Therefore, future 
work on SPRR3 will determine if overexpression of SPRR3 enhances cell 
survival following various challenges.  Specifically, we will expose VSMCs 
overexpressing WT SPRR3 to ROS (in the form of H2O2 added to the media), 
hypoxia, and low serum conditions and asses the rate of cell death by apoptosis.  
Based on the increased phosphorylation of Akt by SPRR3, we expect that those 
cells overexpressing SPRR3 would demonstrate improved survival in the face of 
such insults.  Blocking Akt, however, should abrogate such an effect. 
While it is well known to affect cell survival, Akt has many other functions 
including cell growth, proliferation, transcription, and nutrient metabolism.183  If 
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Figure 5-1 
 
Figure 5-1 
SPRR3 overexpression incre  Akt phosphorylation.  (a) A 
rep 37 
(
 
P  
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ases basal
resentative immunoblot showing phosphorylation of Akt (pAkt) at serine 4
top panel), as well total Akt and βActin.  Levels of pAkt were determined relative 
to total Akt and βActin.  Overexpression of wtSPRR3 resulted in a modest 
increase in pAkt, but this increase was abolished in the Δ1 SPRR3 mutant. 
reincubation with PI3K-inhibitor, LY294002, blocked Akt phosphorylation.  (b)
Quantitation of Akt phosphorylation as assessed by immunoblot (n=4). 
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SPRR3 is not shown to mediate cell survival through Akt as described above, we 
may look at these other phenotypes.  Moreover, while still controversial, data 
exists showing Akt phosphorylation can occur through integrin-linked kinase 
(ILK), which interacts with the cytoplasmic tails of β1 and β3 integrins.184  In 
particular, studies have shown that in VSMCs, ILK is an important mediator of 
cellular behavior by activating Akt.184  It remains unclear, however, if ILK directly 
phosphorylates Akt or if it acts through PI3K (our data supports a role for PI3K, 
as its inhibition abrogates the effect of SPRR3 overexpression).185, 186  
Nevertheless, this supports a role for Akt signaling downstream of integrin 
activation.180    
In addition to our finding that SPRR3 overexpression affects Akt 
phosphorylation, we have also observed an effect on type I collagen synthesis.  
Two-dimensional difference gel electrophoresis (2-D DIGE) of protein lysates 
from VSMC +WT SPRR3 and GFP-control cells showed a significant up-
regulation of type I collagen (Figure 5-2a).  This finding was confirmed by qRT-
PCR and also showed that collagen Ia1 transcripts, which are increased in cells 
overexpressing WT SPRR3, are not up-regulated in cells expressing the D1 
mutant.  This suggests that the amino acids 5-8 are required for this function as 
well (Figure 5-2b).  Especially in light of the requirement for amino acids 5-8 for 
both increased Akt phosphorylation and collagen synthesis, we hypothesized that 
the collagen synthesis may be dependent upon Akt.  In very preliminary data, we 
have shown that increased collagen synthesis by SPRR3 is ablated by the PI3K 
inhibitor, LY294002 (Figure 5-3).  While still very preliminary, these data suggest 
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Figure 5-2 
Figure 5-2 
SPRR3 overexpression increa ollagen expression.  VSMCs 
ove in 
 
 
 
ses type I c
rexpressing WT SPRR3 were found to have increased type I collagen prote
by 2-D DIGE analysis (a) as well as increased collagen I a1 transcript synthesis 
by qRT-PCR (b).  However, cells expressing the Δ1 SPRR3, did not show an 
increase in collagen I a1 transcription (b). 
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Figure 5-3 
 
 
 
Figure 5-3 
SPRR3-dependent collagen up-regulation is Akt-dependent.  WT SPRR3-
overexpressing VSMCs show increased collagen Ia1 transcript levels, but not in 
the presence of the PI3K inhibitor, LY294002. 
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that SPRR3 modulates type I collagen synthesis in an Akt-dependent manner 
(see Figure 5-4).   
Given its known function as a structural element, it is also conceivable that 
SPRR3 may act as a scaffolding protein, by bringing other signaling proteins into 
close proximity (Figure 5-4).  In this way SPRR3 may affect intracellular 
signaling.  Given the known structure and function of SPRR3, it is unlikely that it 
would act in this capacity, as there are no other studied protein-interaction 
domains.  However, the proteomic analysis which identified the WW-binding 
domain also revealed several other putative protein-interaction domain 
sequences.  Most of these were within the highly flexible central domain of the 
protein and are therefore unlikely to be functional.  This remains an area open for 
future study. 
The proposition that SPRR3 modulates intracellular signaling pathways is 
truly a new paradigm for the manner in which the protein is thought to function.  
In recent years, many reports have emerged in which various SPRR family 
members were discovered in tissues other than stratified epithelium.64, 105, 172, 181, 
182, 187-191  Since these tissues are not known to have a cornified epithelium in 
which the SPRR proteins could function, it follows that these proteins must 
perform another role.  It is our hope that this work will be among the first to show 
a new mechanism of action for SPRR proteins, specifically that they can 
participate in signaling pathways, particularly the cell survival pathway via Akt. 
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Figure 5-4 
 
a b 
c 
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Figure 5-4 
Possible models of SPRR3 function.  We have established a role for SPRR3 in 
modulating Akt phosphorylation (a-c).  Given its known function as a structural 
molecule in other systems, it is possible that SPRR3 may act as a scaffold, 
brining various intracellular proteins into proximity, such as integrins or other cell-
surface receptors, and signaling molecules such as PI3K (a).  Furthermore, 
based on the amino acid sequence, SPRR3 may function to modify other 
proteins, thereby acting as a signaling molecule.  As shown in b, it is conceivable 
that SPRR3 may modulate Akt activity by enhancing ILK function downstream of 
integrins.  Finally, in light of studies showing other SPRR family members to be 
turned on in tissue-stress conditions, SPRR3 may function to integrate various 
stress signals (be it mechanical or chemical) through different pathways.  Akt 
could be activated through SPRR3 to activate pathways for increased cell 
survival, such as mTOR and GSK3 (c). 
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SPRR3 knockout mouse 
 In order to gain further understanding into the function of SPRR3, our lab 
generated a mouse deficient in SPRR3.  The mice were aged to over 14 months 
with no evident phenotype.  Since SPRR3 is minimally expressed in VSMCs in 
vivo in the absence of atherosclerosis, and because mice do not naturally 
develop atherosclerosis, it was not surprising that no vascular phenotype was 
observed.  In order to determine what effect the absence of SPRR3 will have in 
atherosclerosis, we plan to cross the SPRR3 knockout mouse with the 
atherosclerosis-prone ApoE knockout mouse.  Based on the data that SPRR3 
overexpression in VSMCs leads to increased migration and decreased 
contraction (which are characteristic of VSMCs in a developing plaque), we 
hypothesize that absence of SPRR3 will decrease atherosclerotic progression in 
the ApoE null mice.   
 Other work from our lab has implicated SPRR3 as biomechanically 
responsive in cardiac tissue, though no cardiac phenotype was evident in the 
knock-out animals.  To further investigate the role of SPRR3 in the heart, we 
subjected SPRR3-null and litter-mate control animals to a pressure-overload 
model of cardiac hypertrophy by transverse aortic constriction.  Surprisingly, the 
SPRR3-/- mice demonstrated improved cardiac function (as determined by 
percentage of fractional shortening) and less fibrosis (Figure 5-5).  Future work 
will further continue to dissect the mechanism by which SPRR3 mediates cardiac 
fibrosis. 
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Figure 5-5 
 
 
 
Figure 5-5 
SPRR3 deletion leads to improved outcome in a mouse model of pressure-
overload cardiac hypertrophy.  Mice deficient for SPRR3 (KO) show greater 
percentage fractional shortening (a) and less fibrosis (b, blue denote collagen 
fibrosis, Masson’s Trichrome Stain) compared to WT controls following 
transverse aortic constriction.  Greater fractional shortening and decreased 
fibrosis indicate improved outcome in the SPRR3-null animals. 
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SPRR3: A lesson on the importance of the microenvironment 
In recent years, growing emphasis has been placed on understanding 
tissue microenvironment of a given system, be it in a tumor, heart disease, or 
normal development.192-194  The atherosclerotic plaque also has a unique 
mélange of ECM composition and compliance, cellular content, cytokines and 
other inflammatory mediators, dead and dying cells, and lipids.195  So complex is 
this microenvironment that it cannot reasonably be completely recapitulated in 
vitro.  In fact, the data presented in chapter III of this document showed a 
requirement for the presence of multiple factors in an in vitro model system in 
order to recapitulate the in vivo results.  In vitro expression of SPRR3 in VSMCs 
occurs only when α1β1 integrins are expressed and bind type I collagen to sense 
cyclic strain.  The absence of any of these components will prevent SPRR3 
expression.43    This demonstrates the need to recapitulate multiple features of 
the in vivo microenvironment when studying vascular biology in vitro.  Not only 
should the cellular and ECM components be consistent with the physiologic 
and/or pathologic context, but the mechanical strains of the system should also 
be accounted for when working in vitro.  This concept could be applied to studies 
of other vascular diseases including atherosclerosis, restenosis, and 
hypertension in addition to stem cell, developmental, and cancer biology.  This 
underscores the growing body of evidence that in vitro cell culture-based work is 
limited in its inability to mimic the in vivo environment.43, 193, 194   
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SPRR3 as a biomarker 
Outside of an understanding of its function, SPRR3 could prove very 
useful as a biomarker for atherosclerosis.  As discussed in earlier chapters, 
expression of SPRR3 in both mouse and human vasculature is restricted to 
regions of atherosclerosis.  Currently, clinically accepted surrogates of risk for 
cardiovascular disease are serum lipid measurements and assessment of the 
inflammatory marker, C-reactive protein (CRP).196-199  However, these markers of 
atherosclerosis are somewhat non-specific and only partially predictive.196  At 
their 57th Annual Scientific Session in 2008, the American College of Cardiology 
concluded that many of the currently accepted surrogate markers of 
cardiovascular events and atherosclerosis are not sufficiently predictive, and 
therefore bear further evaluation.200  Furthermore,  a single, definitive histological 
marker of atherosclerosis does not exist.201   
Markers of atherosclerosis fall into three general categories: those used 
for histological detection (and therefore on non-living tissue), those detected in 
the peripherally circulating blood or urine, and those which are detected through 
various imaging modalities.201  Tests which analyze proteins and molecules from 
peripheral blood or urine samples are most economical, least invasive, relatively 
fast, and are therefore preferred compared to imaging studies.197  Ideally, 
development of new biomarker tests should meet the following criteria: 1) they 
should provide novel data beyond what can be determined by other tests, 2) the 
marker in question should be stable and not change from day to day nor with 
respect to time of day or diet, and 3) the marker should be reasonably simple and 
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inexpensive to test.197  The tests which are currently used in a clinical setting 
measure serum lipid levels, specifically triglycerides, HDL, and LDL.  Certain 
cutoff points have been established over which levels of these markers are 
considered to put an individual at risk for atherosclerosis, coronary artery 
disease, and myocardial infarction.202  While these are statistically predictive of 
atherosclerosis and other clinical events, there remain individuals who had a lipid 
profile well within the normal range at the time of suffering a cardiovascular 
event.197  Thus, other indicators of subclinical atherosclerosis have been sought, 
with CRP being the most successful marker identified to date.196, 197, 199  As a 
marker of inflammation, CRP levels in the serum can reflect vascular 
inflammation, the most common cause of which is atherosclerosis.  While it has 
been established that CRP does not significantly promote atherosclerosis, serum 
levels of CRP have been clearly correlated with increased risk of congestive 
heart disease and a clinically significant event.199  Nevertheless, CRP is not a 
definitive marker of atherosclerotic burden, as CRP is a non-specific pro-
inflammatory molecule and can be elevated by other inflammatory events.196, 203  
While CRP levels are a well-established marker of atherosclerosis and will 
undoubtedly continue to be used as a risk indicator, other biomarkers are being 
considered for development.  Most of these are related to the inflammatory 
processes involved in atherosclerosis, such as CD40 ligand, IL-6, adiponectin, 
interleukin 18, and MMP9.  However, none of these are yet as promising as 
CRP.197  Therefore, the need for a highly specific atherosclerosis marker 
remains. 
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Imaging technology is a rapidly growing field and has been applied to 
studying atherosclerosis.  While more expensive than clinical chemistry tests, 
imaging can provide more precise and accurate information such as location, 
size, and vulnerability of a plaque.  Several invasive techniques such as 
angiography, intravascular ultrasound, thermography, and optical coherence 
tomography have been used for investigating the nature and extent of 
atherosclerotic plaques.  However, these are expensive and complicated 
procedures.  More desirable are the non-invasive approaches such as magnetic 
resonance imaging, CT scanning, and nuclear imaging.201  Moreover, these 
modalities are being adapted to identify tracers targeted against specific 
molecules within the atheroma.204  A highly specific marker for atherosclerosis 
would certainly aide in the development of an ideal imaging protocol, and could 
someday enable clinicians to determine an accurate measurement of plaque 
development in an individual.201, 204   
As a highly specific marker of atherosclerosis, SPRR3 could theoretically 
be used as clinical marker, either in an assay to detect levels of SPRR3 in serum 
or urine, or in an imaging test.  We currently have no data to indicate that SPRR3 
is secreted and would therefore be found in the blood or urine.  We have 
observed that SPRR3 may be released from VSMCs, probably as the cells die 
during plaque progression.43  Therefore, it is possible that SPRR3 may be 
released from the vessel wall.  Furthermore, SPRR3 could be used as a label for 
specific imaging of atheromas.  Alternatively, work from our lab has also 
demonstrated specificity of integrin α1β1 expression for VSMCs within 
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atheromas, and could conceivably also be used as a marker for 
atherosclerosis.43  This is particularly appealing as integrins localize to the cell 
surface and therefore are more easily accessed by markers.  Such work is still 
theoretical, but will hopefully be developed in the future.  
Finally, it is our hope that SPRR3 will be adopted as a histological marker 
of atherosclerosis.  While a trained pathologist can generally recognize moderate 
to advanced atheromas in a paraffin-embedded tissue section, early lesions can 
be more difficult to identify.7  Since immunostaining against SPRR3 specifically 
highlights regions of atherosclerosis, even when a lesion would otherwise be 
difficult to find on an H&E-stained section (early lesions such as fatty streaks, as 
well as in vein graft atherosclerosis), SPRR3 could be developed for use as a 
histological marker of atheromas in tissue sections.43, 164, 199   
 
Closing 
 Atherosclerosis is a major cause of mortality in the United States; 
therefore, gaining insight into the pathophysiology of the disease is of great 
interest.205  The biomechanics of atherosclerotic initiation and progression is a 
new but growing field of research.  SPRR3 expression in atheromas is regulated 
by cyclic strain as sensed through integrin α1β1 binding to collagen I.  These 
studies shed light onto the role of biomechanics in gene regulation, particularly in 
vascular pathologies such as atherosclerosis.   
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